 
CLINICAL  STUDY  PROTOCOL 
TITLE PAGE  
 
Protocol Title:  A Phase 1b, Open-L abel, Boost-O ptimization Study of an Adenoviral- 
vector B ased O ral Norovirus V accine (VXA -G1.1 -NN) Expressing 
GI.1 VP1 A dministered Orally to Healthy Adult Volunteers  
Protocol Number:  VXA- NVV -[ADDRESS_137934]  Name:  [CONTACT_122727].1 Norwalk VP1 Vaccine, Oral E1- /E3-Deleted  
Replication Defective Recombinant Adenovirus 5 with double -stranded  
RNA Adjuvant  (VXA-G1.1- NN) 
Indication:  Prevention of  noroviral gastroenteritis  caused  by [CONTACT_122681].[ADDRESS_137935] 
South San  Francisco,  CA [ZIP_CODE] 
U.S. IND Number  IND: [ADDRESS_137936]  Management  
Phone: [PHONE_2781] 
Email: [EMAIL_2444]  
Medical  Monitor Dave Liebowitz,  MD, PhD 
Phone: +1  ([PHONE_2782] 
Email: [EMAIL_2445]  
Version and 
Approval Date                Amendment 1 ; August 25, 2021  
 
Previous version            Original; March 31, 2021 
 
Confidentiality  Statement  
This document is confidential and is to be distributed for review only to investigators, potential investigators,  
consultants, study staff, and applicable independent Ethics Committees and/or Institutional Review Boards.  
The conte nts of this document shall not be disclosed to others without written authorization from Vaxart (or  
authorized  designees) unless  it is necessary  to obtain  informed  consent  from  potential  study  participants.  
VAXART  Protocol  Number:  VXA -NVV -[ADDRESS_137937] 25 2021  Page 2 of 62   
SIGNATURE [CONTACT_1783]/STATEMENT OF  COMPLIANCE 
 
 
Title:  A Phase 1b, open- label, boost -optimization study of an adenoviral - 
vector based oral norovirus vaccine (VXA -G1.1-NN) expressing 
GI.1 VP1 administered orally to health y adult volunteers 
 
Protocol Number:  VXA- NVV-105 (Amendment 1)  
 
 
 
Vaxart,  Inc.:    Date   
 
  
 
The study will be conducted in accordance with the International Council for Harmonisation (ICH) E6 and the Code of Federal Regulations on the Protection of Human Subjects (45 CFR Part 46). Except where necessary to eliminate an immediate hazard(s) to the study participants, the Principal Investigator [INVESTIGATOR_7433], or changes to the protocol will take place without prior agreement  from the Sponsor and documented approval from the  Institutional 
Review Board (IRB) and/or Independent Ethics Committee (IEC). All personnel involved in the conduct of this study have completed Human Subjects Protection Training. 
 
 
I agree  to ensure that  all staff members  involved in the conduct of this study  are inform ed about 
their obligations in meeting  the above commitments.  
  
 
 
Principal  Investigator:  
 
 
[CONTACT_5627]:     
Signature 
 
      
[CONTACT_1782]  
(Print)    
 
Site & Address:   
    
 
 
 
 
 
  
 
 
VAXART  Protocol  Number:  VXA -NVV -[ADDRESS_137938]  25 2021   Page 3 of 62  TABLE OF  CONTENTS  
TITLE PAGE  ............................................................................................................................ 1 
SIGNATURE [CONTACT_1783]/STATEMENT OF  COMPLIANCE ................................................... [ADDRESS_137939] OF TABLES  .......................................................................................................................................................... 5 
1. PROTOCOL SUMMARY  ........................................................................................... 6 
1.1. SYNOPSIS  ....................................................................................................................................................... 6 
1.2. SCHEDULE  OF ACTIVITIES  ...................................................................................................................... 10 
2. INTRODUCTION.  ...................................................................................................... 12 
2.1. STUDY RATIONALE  .................................................................................................................................. 12 
2.2. BACKGROUND  ............................................................................................................................................ 13 
2.3. BENEFIT /RISK ASSESSMENT  ................................................................................................................. 13 
2.3.1.  Benefit  Assessment  ................................................................................................................... 14 
2.3.2.  Overall  Benefit/Risk  Conclusion  .............................................................................................. 14 
3. OBJECTIVES  AND ENDPOINTS  ........................................................................... 15 
4. OVERALL  STUDY DESIGN .................................................................................... 16 
4.1. SCIENTIFIC  RATIONAL  FOR STUDY DESIGN ..................................................................................... 17 
4.2. JUSTIFICATION FOR VARYING DOSE SCHEDULES  ............................................................. 17 
4.3. STUDY DURATION .................................................................................................................................... 17 
4.4. END OF STUDY DEFINITIONS  ................................................................................................................. 17 
4.5. 4.5.   SAFETY AND FINAL DATABASE  Lock ....................................................................... 17 
5. ELIGIBILITY CRITERIA  ........................................................................................ 18 
5.1. INCLUSION CRITERIA  ............................................................................................................................... 18 
5.2. EXCLUSION  CRITERIA  .............................................................................................................................. 19 
5.3. SCREEN  FAILURES  .................................................................................................................................... 21 
6. STUDY DRUG, CONCOMITANT THERAPY AND LIFE- STYLE 
CONSIDERATIONS  .................................................................................................. 22 
6.1. STUDY DRUG  ADMINISTRATION  .......................................................................................................... 22 
6.2. COMPLIANCE  OF STUDY DRUG  ............................................................................................................. 23 
6.2.1.  Dose Adjustments/Modifications/Delays.  ................................................................................. 23 
6.3. HANDLING AND  ACCOUNTABILITY  ..................................................................................................... 23 
6.4. TREATMENT OF OVERDOSE  ................................................................................................................... 25 
6.5. CONCOMITANT  THERAPY  ....................................................................................................................... 25 
6.5.1.  Prohibited  Concomitant  Medication  ......................................................................................... 25 
6.6. INTERVENTION  AFTER  THE END OF THE  STUDY ............................................................................. 25 
7. DISCONTINUATION OF STUDY DRUG AND PARTICIPANT 
WITHDRAWAL FROM  STUDY  ............................................................................. 26 
7.1. DISCONTINUATION OF STUDY DRUG .................................................................................................. 26 
7.2. Early Termination Visit (Active or Follow -Up Period) ………………………….…………… 27 
7.3. PARTICIPANT  WITHDRAWAL  FROM  THE  STUDY  ............................................................................. 27 
VAXART  Protocol  Number:  VXA -NVV -[ADDRESS_137940]  TO FOLLOW -UP ............................................................................................................................... 27 
8. STUDY ASSESSMENTS AND PROCEDURES  ..................................................... 28 
8.1. IMMUNOGENICITY ASSESSMENTS ....................................................................................................... 28 
8.2. SAFETY  ASSESSMENTS  ............................................................................................................................ 29 
8.2.1.  Physical Examination  ................................................................................................................ 29 
8.3.        VITAL SIGNS .................................................................................................................. 29 
8.3.1       Clinical Safety Laboratory Assessments  .................................................................................. 29 
8.4.          ADVERSE EVENTS AND SERIOUS ADVERSE EVENTS ......................................................29 
8.4.1.    Time Period and Frequency for Collecting AE, SAE and Other Reportable  
 Safety Event Information  .......................................................................................................... 30 
8.4.2      Method of Detecting AEs and SAEs  ......................................................................................... 32 
8.4.3.    Follow -up of AEs and SAEs  ..................................................................................................... 32 
8.4.4.    Regulatory Reporting Requirements for SAEs  ......................................................................... 32 
8.4.5.    Death Events  ............................................................................................................................. 32 
8.4.6.    Pregnancy  .................................................................................................................................. 32 
9. STATISTICAL CONSIDERATIONS  ...................................................................... 33 
9.1. SAMPLE SIZE DETERMINATION  ............................................................................................................ 33 
9.2. STATISTICAL ANALYSES  ........................................................................................................................ 33 
9.2.1.  Safety  Analysis  ......................................................................................................................... 34 
9.2.2.  Immunogenicity Anal ysis ......................................................................................................... 35 
9.3. SAFETY  OVERSIGHT  ................................................................................................................................. 35 
9.3.1.  Internal  Sponsor  Review  ........................................................................................................... 35 
10. SUPPORTING DOCUMENTATION AND OPERATIONAL 
CONSIDERATIONS  .................................................................................................. 37 
10.1. APPENDIX 1: REGULATORY , ETHICAL , AND STUDY OVERSIGHT  CONSIDERATIONS  ........37 
10.1.1.  Regulatory and Ethical Considerations  ..................................................................................... 37 
10.1.2.  Financial  Disclosure .................................................................................................................. 37 
10.1.3.  Informed  Consent  Process  ......................................................................................................... 38 
10.1.4.  Exclusion  of Women,  Minorities, and Children  (Special  Populations)  .................................... 38 
10.1.5.  Data Protection  .......................................................................................................................... 38 
10.1.6.  Dissemination  of Clinical Study  Data ....................................................................................... 39 
10.1.7.  Data Quality  Assurance ............................................................................................................. 39 
10.1.8.  Source  Documents  .................................................................................................................... 39 
10.1.9.  Publication  Policy  ..................................................................................................................... 40 
10.2. APPENDIX 2: SAFETY  CLINICAL  LABORATORY  TESTS  ................................................................ 41 
10.3. APPENDIX 3: A DVERSE EVENTS : DEFINITIONS AND PROCEDURES FOR RECORDING , 
 EVALUATING , FOLLOW -UP, AND REPORTING  ................................................................................. 42 
10.4. APPENDIX 4: C ONTRACEPTIVE GUIDANCE AND COLLECTION OF PREGNANCY 
INFORMATION  ........................................................................................................................................... 50 
VAXART  Protocol  Number:  VXA -NVV -[ADDRESS_137941]  25 2021   Page 5 of 62  10.4.1.  Definitions  .................................................................................................................................  50 
10.4.2.  Contraception Guidance ............................................................................................................ 50 
10.4.3.  Collection  of Pregnan cy Information  ........................................................................................ 50 
10.5. APPENDIX 5: ADVERSE  EVENTS  OF SPECIAL  INTEREST (AESI S) .................................... 51 
10.6. APPENDIX 6: ABBREVIATIONS  ............................................................................................................. [ADDRESS_137942] of Tables  
 
Table 1  Treatment  Arm,  Doses and Sample  Size  ................................................................. 9 
Table 2  Schedule  of Activities  ............................................................................................ 10 
Table 3  Risk Assessment  .................................................................................................... 14 
Table 4  VXA- G1.1- NN Study Drug ................................................................................... 22 
Table 5  Adverse  Event Reporting Timeline s to the Sponsor  .............................................. 31 
Table 6  Protocol -Required Safety  Laboratory Assessments  .............................................. 41 
Table 7  Definition of AE (Unsolicited and Solicited)  ........................................................ 42 
Table 8  Events Meeting Definition of AE  .......................................................................... 42 
Table 9  Definition of S AE .................................................................................................. 43 
Table 10     Definition of AESI and NOCI……………………………………………………43 
Table 1 1 Recording of AE and/or SAE  ................................................................................ 44 
Table 1 2 Grading the Seve rity of AEs  .................................................................................. 45 
Table 1 3 Grading of Solicited  Symptoms of Reactogenicity  ............................................... 46 
Table 1 4 Grading of Laboratory  Abnormalities (Serum Chemistry)  ................................... 47 
Table 1 5 Grading of Laboratory  Abnormalities (Hematology)  ............................................ 47 
Table 1 6 Grading of Laboratory  Abnormalities (Urinalysis)  ............................................... 48 
Table 1 7 Assessment  of Causality  ........................................................................................ 48 
Table 1 8 Reporting of  SAEs  ................................................................................................. 49 
VAXART  Protocol  Number:  VXA -NVV -[ADDRESS_137943] -optimization study of an adenoviral - vector based oral norovirus 
vaccine (VXA -G1.1- NN) expressing GI.1 VP1 administered orally to healthy adult volunteers . 
 
Study  Rationale  and Hypothesis  
VXA- G1.1- NN is an E1/E3 -deleted, replication -incompetent, adenovirus 5 (Ad5) vaccine  
vectors designed for use as an oral vaccine for the prevention of noroviral gastroenteritis caused  
by [CONTACT_122682].1. The monovalent vaccine vector encodes the full -length of viral  
protein 1 (VP1) gene of Norwalk virus (Norovirus GI.1). The adjuvant consists of a double - 
stranded RNA Toll -like receptor 3 (TLR3) agonist which enhances immune induction to 
expressed  antigen in the gut mucosa.  
Noroviruses are a genetically diverse group of small, non -enveloped, single -stranded positive  
sense RNA viruses belonging to the Caliciviridae family (Bresee, 2002). Norovirus infections are  
a leading cause of sporadic and epi[INVESTIGATOR_122658] (Hoa  
Tran, 2013; de  Graaf,  2016) . There is  an urgent  public health  need for  rapid development  of 
novel  interventions  to prevent  the spread  of this disease,  inclu ding prophylactic  measures,  such  
as vaccines (Esposito, 2020). 
A unique and advantageous immune response elicited by [CONTACT_122683]. Given that the mucosal route of immunization produces  
superior mucosal immunity compared to injected vaccines, it is hypothesized that VXA -G1.1-  
NN oral vaccine may enable higher degrees of mucosal protection against infection when 
compared  to a parenteral immunization method.  
VXA- G1.1- NN is designed to elicit both antibody and T cell responses, mucosally and 
systemically, to Norovirus GI.[ADDRESS_137944] Technology (VAASTTM) platform have demonstrated  
protective immunity to viruses, such as norovirus, influenza, and respi[INVESTIGATOR_4345], with 
both systemic and mucosal immune responses against the antigen of choice ( Kim, 2016; Kim , 
2018; Liebowitz, 2020).  
Clinical data is available from 3 Phase 1 studies (VXA - NVV -101, VXA -NVV- 102, and 
VXA- NVV- 103) which evaluated multiple single - and multi -dose ranging of the monovalent  
vaccine VXA -G1.1- NN in over 200 healthy young adult subjects (18 to 49 years old). These  
studies indicate that the vaccine was tolerated well and generated robust immune responses including systemic and mucosal  antibodi es as well  as memory  immunoglobulin A (IgA)/ 
immunoglobulin G (IgG). In addition to increase in serum blocking titer fifty assay (BT50) titers,  
vaccine recipi[INVESTIGATOR_122659]1 -specific circulating antibody secreting  
cells (AS Cs), IgA
+ memory B cells expressing gut -homing receptor (α4β7), and fecal IgA, 
indicating substantial and local responses potentially relevant to prevent norovirus infection  
(Kim, 2018). 
VAXART  Protocol  Number:  VXA -NVV -[ADDRESS_137945] been 
strongly reliant, among other technologies, on the use of adeno- associated viral vectors (AAV) 
(Callaway, 2020). AAV- based COVID- 19 vaccines from [COMPANY_008], [COMPANY_012], and the 
Gamaleya Research Institute of Epi[INVESTIGATOR_122660]. Contextually, emerging evidence generated in clinical settings with the AstraZen eca COVID-19 vaccine (AZD1222) indicates that a 12- week interval 
between vaccine doses might significantly improve efficacy and immunogenicity of AAV- based 
vaccination strategies compared to a shorter 4 - or 6 -week dosing interval ( Voysey et al., 2021; Hung 
and Poland, 2021). Specifically, subjects who received two vaccine doses with a dose interval of at least 12 weeks showed neutralizing and anti- SARS -CoV-2 spi[INVESTIGATOR_122661]-fold higher than those who received the two-dose regimen at an interval of less than 6 weeks. 
Accordingly, AZD1222 vaccine efficacy increased from 55% (<6- week interval) to 81% with an 
interval of at least 12 weeks. In light of these findings, the current Phase 1b study VXA- NVV-105 is 
designed to assess the safety  and immunogenicity of the VXA-G1.1- NN vaccine with a 2 -dose 
vaccination schedule using different repeat -dosing intervals (4, 8, or 12 weeks apart) in healthy 
young adults (18 to 55 years old).  
The current  phase 1b, open-label, boost-optimization study objectives and endpoints for an 
adenoviral- vector based oral norovirus vaccine (VXA -G1.1-NN) expressing GI.1 VP1 
administered orally to health y adult volunteers  is presented below . 
Objectives and Endpoints  (Primary  and Secondary)  
Objectives  Endpoints  
Primary  
• To evaluate the immunogenicity of VXA-
G1.[ADDRESS_137946] schedules ( Week 
4, [ADDRESS_137947] initial dose ) in healthy  adult s 
aged 18-55 , inclusive  • VP1 specific IgA ASC by [CONTACT_28745]-linked  
immunospot  (ELISpot)  
• Norovirus G1.1 histo-blood group antigen 
(HBGA)  blocking antibodies  (BT50) 
• VP1 specific serum IgG by [CONTACT_122684] (MSD) assay  
•  
Secondary  
• To assess the safety and tolerability of 
VXA- G1.[ADDRESS_137948]  schedules 
(Week 4, 8 or 12)  in healthy adults aged 
18-55, inclusive  • Frequency, duration, and severity of  
solicited symptoms of reactogenicity  
(local,  systemic) for 1 week  following  
each dose of  study drug  
• Frequency, duration, and severity of  
unsolicited  serious AEs (SAEs), AEs of 
special interest (AE SIs) and New Onset of 
Chronic Illness (NOCIs) through  each Study 
Period  ([ADDRESS_137949] each vaccination ) 
 
VAXART  Protocol  Number:  VXA -NVV -[ADDRESS_137950] 25 2021  Page 8 of 62  Overall Design  
This is an open- label  study in healthy adult participants age 18-55 years old. The study will 
enroll 30 subjects to one of three  treatment cohorts. 
 
Cohort 1: (4-week boost vaccination ) 10 subjects will receive two doses of 1x1010 IU± 0.5 log 
at Day 1 an d Week 4  
Cohort 2: (8- week  boost vaccination ) 10 subjects will receive two doses of 1x1010 IU± 0.5 log 
at Day 1 and Week 8  
Cohort 3: (12-week boost vaccination) 10 subjects will receive two doses of 1x1010 IU± 0.5 log 
at Day 1 and Week 12  
The study will include a screening period, Study Period 1 (Day [ADDRESS_137951] initial 
vaccination), Study Period 2 (4 Weeks from second vaccination will be initiated  at Week 4 f or 
Cohort 1, Week 8 for Cohort 2 and Week 12 for Cohort 3), and a follow-up period of [ADDRESS_137952] second vaccination in each cohort. Study assessments will be conducted as shown in the Schedule of Activities (SoA) in Section 1.2 (Table 2) . In addition, participants will be contact[CONTACT_122685]. 
After signing an info rmed consent, participants will undergo screening assessments to determine 
study eligibility within a 45-day screening period. 
Eligible  participants will be enrolled and receive their  first dose of study vaccine on Day  1. 
During the Active study period, participants will record any potential symptoms of 
reactogenicity daily for [ADDRESS_137953] safety assessments and  samples  collected for 
evaluation of immunogenicity. 
At the participant ’s second vaccination visit (Week 4, 8 or 12 depending on Cohort assignment) 
they will have pre- dose sa fety assessments to determine eligibility to continue  with the second 
vaccination. Additionally,  female  participants  of childbearing potential must  have a negative 
pregnancy test  before receiving their second vaccination. Particip ants deemed ineligible for the 
second  vaccination due to acute illness or new medical condition may be re- assessed, and if the 
condition resolves, may have a delayed second vaccination within 1 week of their scheduled 
vaccination Visit (+7 days window from W eek 4, 8 or 12 depending on Cohort assignment). 
Participants with a delayed second vaccination will follow the  delayed  schedule through  the rest 
of their Active Period as specified in the SoA . 
If a subject  remains ineligible for the second vaccination, they will com plete an  Early 
Termination visit and then enter  the scheduled f ollow -up period per Cohort assignment as 
outlined in the SoA ( 1.2).   
All participants will enter the f ollow -up period [ADDRESS_137954] samples collected for  evaluation  of immunogenicity as specified  in the SoA. 
 
VAXART  Protocol  Number:  VXA -NVV -[ADDRESS_137955]  25 2021   Page 9 of 62  Intervention Group and Number of Participants  
Table 1  Treatment Arm, Doses and Sample Size  
Group Study  Drug  Dose  (IU ±0.5  log) No. of Doses  Dosing  Schedule  No. of Subjects  
Cohort 1  VXA -G1.1 -NN 1x1010 2 Day 1 & Week 4a 10 
Cohort 2  VXA -G1.1 -NN 1x1010 2 Day 1 & Week 8a 10 
Cohort 3  VXA -G1.1 -NN 1x1010 2 Day 1 & Week 12a 10 
Total  30 
a Subjects not eligible for the second dose (within the 7-day dosing window) will immediately enter the follow -up period . 
 
 
 
  
 
Study  Duration  for Each  Participant  
For each  subject,  study participation  is expected  to last as follows: 
 
Study Period Cohort 1  
(Day 1 and Week 4)  Cohort 2  
(Day 1 and Week  8)  Cohort 3  
(Day 1 and Week 12)  
Screening  Period:  45 days 45 days  45 days  
Study Period 1:  4 weeks (Day 1 –  Week 4)  4 weeks (Day 1 –  Week 4)  4 weeks (Day 1 –  Week 4)  
Study Period 2:  4 weeks (Week 4 –  8) 4 weeks (Week 8 –  12) 4 weeks (Week 12 –  16) 
Follow -Up Period:  [ADDRESS_137956]  
Total Duration  7 Months  8 Months  9 Months  
 
Safety  Monitoring  Committee  (SMC): No  
VAXART  Protocol  Number:  VXA -NVV -[ADDRESS_137957] 2021    Page 10 of 62  1.2  Schedule  of Activities  
Active Period  
 Screen  Study Period 1 – Cohorts 1, 2, 3   
   Study Period 2 – Cohort 1   
   Study Period 2 – Cohort 2   
   Study Period 2 – Cohort 3  
Study Day  -45d to  
–1 d Day 1  
(Wk 0)  Day 8  
(Wk 1)  Day 29  
(Wk 4)  Day 36  
(Wk 5)  Day 57  
(Wk 8) /ET1 Day 64  
(Wk 9)  Day 85  
(Wk  12)/ET2 Day 92  
(Wk 13)  Day 113  
(Wk16)/ET3 
Visit Window (days)   n/a 0 ±2 0 ±2 0 ±2 0 ±2 
Informed  consent  X          
Inclusion/Exclusion  X X  X       
Demographics  X          
Medical  history  X          
Stool  for occult  blood  X          
Blood Sample (HBsAg,  HCV,  
HIV)  X          
Urine  drug screen  X          
Alcohol Testing  X          
Pregnancy  Testa X X  X1  X2  X3   
Physical  examination  X Xb Xb Xb Xb Xb Xb Xb Xb Xb 
Vital  Signs  X X X X X X X X X X 
Safety  laboratory  tests X Xc X X X X X X X X 
Urinalysis  X X X X X X X X X X 
COVID vaccination status  X          
Vaccination   X  X1, d,e  X,2, d,e  X3, d,e   
Dispense Solicited Symptom Diary   X1,2,3  X1  X2  X3   
Review & Collect Solicited 
Symptom Diary    X  X1  X2  X3  
Review prior & concomitant 
medication  X X X X X X X X X X 
Query for AEs, SAEs, AESIs and 
NOCIs   X X X X1,f X1,f X2,f X2,f X3,f X3,f 
Sample  Collection  Immunogenicity  Assessments  
Serum    X1,2,3 ,g  X1,2,3  X1,2  X2,3  X3 
Whole blood (Flow  Based)   X1,2,3 X1,2,3 X1 X1 X2 X2 X3 X3  
Whole blood (PBMC)   X1,2,3 X1,2,3 X1 X1 X2 X2 X3 X3  
Nasal  Swab  (Sam  Device)   X1,2,3  X1,2,3  X1,2  X2,3  X3 
Saliva  Sample   X1,2,3  X1,2,3  X1,2  X2,3  X3 
VAXART  Protocol  Number:  VXA -NVV -[ADDRESS_137958] 2021    Page 11 of 62  AE, adverse vent; AESI, Adverse event of special interest; EOS, End of Study; ET, Early Termination (7.2);  HCV, Hepatitis C Virus; HIV, Human Immunodeficiency Virus; NP, 
Nasopharyngeal; NOCI, New Onset of Chronic Illness; PBMC, peripheral blood mononuclear cells; SAE, serious adverse eve nt. 
1 = Cohort 1; 2 = Cohort 2; 3  = Cohort 3.  
a For women  of childbearing potential. Test at Day 1 and at second dose (boost). Test can be serum or urine  test. 
b Targeted . 
c If screening lab tests are performed within [ADDRESS_137959] a delayed 2nd dose 
within  1 week  of scheduled visit . 
e If participants are not eligible to receive their 2nd dose, they immediately enter the follow-up period.  
f AEs will only be collected for 4 weeks following each study drug administration . 
g.An aliquot of serum collected at baseline will be stored for testing (e.g. Platelet Factor 4 [PF4 ] antibody ELISA) should an AESI related to blood clots be reported anytime during 
the study period.  
 
 
Follow -Up Period  
 COHORT 1  COHORT 2  COHORT 3  
Study  Day Months  3, 4, 
5, 6 Month  7 
(Wk 28)/ EOS  Months  4, 
5, 6, 7   Month 8 
(Wk 32)/EOS  Months  5, 6, 7, 
8 Month 9 (Wk 36)/ 
EOS  
Telephone  Visit   X  X  X  
Visit  Window  (days)  ±7 ±7 ±7 ±7 ±7 ±7 
Query for SAEs, AESIs and 
NOCIs  X X X X X X 
Sample  Collection  Immunogenicity  Assessments  
Serum    X  X  X 
Whole blood (Flow  Based)        
Whole blood (PBMC)a  X  X  X 
Nasal  Swab  (Sam  Device)   X  X  X 
Saliva    X  X  X 
AE, adverse event; AESI, Adverse event of special interest; EOS, End of Study;  ET, Early Termination;   HCV, Hepatitis C Virus; HIV, Human Immunodeficiency Virus; NP, 
Nasopharyngeal; NOCI, New Onset of Chronic Illness; PBMC, peripheral blood mononuclear cells; SAE, serious ad verse event . 
a Optional. 
 
 
VAXART  Protocol  Number:  VXA -NVV -[ADDRESS_137960]  2021   Page 12 of 62   
2. INTRODUCTION  
 
2.1. Study  Rationale  
VXA- G1.1- NN is an E1/E3 -deleted, replication -incompetent, adenovirus 5 (Ad5) vaccine  
vectors designed for use as an oral vaccine for the prevention of noroviral gastroenteritis caused  
by [CONTACT_122682].1. The monovalent vaccine vector encodes the full -length of viral  
protein 1 (V P1) gene of Norwalk virus (Norovirus GI.1). The adjuvant consists of a double - 
stranded RNA Toll -like receptor 3 (TLR3) agonist which enhances immune induction to 
expressed  antigen in the gut mucosa.  
Noroviruses a re a genetically diverse group of small, non -enveloped, single -stranded positive  
sense RNA viruses belonging to the Caliciviridae family (Bresee, 2002). Norovirus infections are  
a leading cau se of sporadic and epi[INVESTIGATOR_122658] (Hoa  
Tran, 2013; de  Graaf,  2016). There is  an urgent  public health  need for  rapid development  of 
novel  interventions  to prevent  the spread  of this disease,  including prophylactic  measures,  such  
as vaccines (Esposito, 2020). 
A unique and advantageous immune response elicited by [CONTACT_122683]. Given that the mucosal route of immunization produces 
superior mucosal immunity compared to injected vaccines, it is hypothesized that VXA -G1.1-  
NN oral vaccine may enable higher degrees of mucosal protection against infection when  
compared  to a parenteral immunization method.  
VXA- G1.1- NN is designed to elicit both antibody and T cell responses , mucosally and 
systemically, to Norovirus GI.[ADDRESS_137961] Technology (VAASTTM) platform have demonstrated  
protective immunity to viruses, such as norovirus, influenza, and respi[INVESTIGATOR_4345], with 
both systemic and mucosal immune responses against the antigen of choice (Kim, 2016; Kim,  
2018; Liebowitz, 2020).  
Clinic al data is available from 3 Phase 1 studies (VXA - NVV -101, VXA -NVV- 102, and 
VXA- NVV- 103) which evaluated multiple single - and multi -dose ranging of the monovalent  
vaccine VXA -G1.1- NN in over 200 healthy young adult subjects (18 to 49 years old). These  
studies indicate that the vaccine was tolerated well and generated robust immune responses including systemic and mucosal  antibodi es as well  as memory  immunoglobulin A (IgA)/ 
immunoglobulin A (IgG). In addition to increase in serum blocking titer fifty assay (BT50) titers,  
vaccine recipi[INVESTIGATOR_122659]1 -specific circulating antibody secreting  
cells (ASCs), IgA
+ memory B cells expressing gut -homing receptor (α4β7), and fecal IgA, 
indicating substantial and local responses potential ly relevant to prevent norovirus infection  
(Kim, 2018). 
The current Phase 1b study is designed to assess the immunogenicity of VXA -G1.1- NN with 
repeat -dose administration at Day 1 and 2nd vaccination at  Weeks 4, 8 or 12 ( depending on 
Cohort assignment) in healthy adults aged 18- 55, inclusive, with varying boost  schedules.  
 
2.2.  Background  
Noroviruses are a leading cause of foodborne disease and outbreaks of gastroenteritis worldwide  
and are responsible for substantial morbidity, mortality, and healthcare costs (Bányai, 2018). The  
VAXART  Protocol  Number:  VXA -NVV -[ADDRESS_137962]  2021   Page 13 of 62  virus affects people of all ages; however, the incidence of disease is higher in younger children 
and in adults ≥65 years old (Lopman, 2016; Esposito, 2020) . Noroviruses are highly infectious  
with major mode of transmission by [CONTACT_122686]- oral spread, usually via contaminated food or water  
(Teunis, 2008; de Graaf, 2016; Gaythorpe, 2018) . The incubation period of norovirus is 10- 51 
hours.  
Noroviruses are genetically diverse viruses. Genogroups I, II and IV are human- transmitted.  
Genogroup I and II account for the majority of norovirus outbreaks (Vega, 2014) . Each  
genogroup is further divided into genotypes based on the similarity of the amino acid sequence  
of the majo r viral capsid protein, VP1. Genotypes GI.[ADDRESS_137963] outbreaks and the majority  of the  disease burden globally (Lopman, 2016).  
Norovirus causes e xtensive morbidity with clinical symptoms of nausea, vomiting, non -bloody 
diarrhea, and abdominal cramps. Fever, headache, and body aches have been reported as well.  
These symptoms usually last [ADDRESS_137964] treatment is oral rehydration with fluids and electrolytes  
(Glass,  2009). There  are currently  no licensed  vaccines for  norovirus.  
Norovirus is an enteric pathogen and infects the epi[INVESTIGATOR_122662]. Vaxart’s  
platform is based on oral delivery of the vaccine to the intestinal mucosa, which is analogous to 
the natural route of norovirus infection and entry. Human and animal experience with Vaxart’s  
orally administered platform has demonstrated that substantial t ransgene specific intestinal IgA  
responses can be generat ed in addition to systemic IgG responses to the expressed antigen  
(influenza HA and norovirus VP1). These platform attributes may allow for better protection  
against  norovirus infection than an injec ted protein- based vaccine.  
As indicated,  VXA- G1.[ADDRESS_137965]  
immune responses. In study VXA -NVV- 101, the primary immunological endpoint (increase in 
BT50 titers) was met in the high -dose group (P = 0.0003), with 78% showing a ≥2- fold rise in  
titers after a single immunization (Kim, 2018) . Statistically significant increases in geometric  
mean  titers  were  also seen  in Study VXA- NVV- 103 with  VXA- G1.1- NN compared  with  placebo  
(p=0.0008), with 43% of  subjects showing a ≥[ADDRESS_137966]  vaccination.  
A detailed  description  of the chemistry,  pharmacology, efficacy,  and safety  of VXA- G1.1- NN is  
provided in the Investi gator’s Brochure (IB).  
 
2.3.  Benefit/Risk Assessment  
More detailed information about the known and expected benefits and risks and reasonably 
expected  adverse events of  VXA- G1.1 -NN may be  found in the IB. 
 
 
  
 
  
 
 
 
VAXART  Protocol  Number:  VXA -NVV -[ADDRESS_137967]  2021   Page 14 of 62  Table 3  Risk  Assessment  
Clinical ly Significant Risk  Summary  of Data/Rationale for  Risk  Mitigation  Strategy  
Study  Drug  VXA- G1.[ADDRESS_137968] the 
potential to cause allergic reactions.  
Vaccine components including  immunizing 
antigens, adjuvants, culture  derived proteins 
(e.g., gelatin) and other  agents may have the 
potential to cause  complications. Monitor participants for any allergic reactions and onset of new illness during  the 
active and  follow -up period.  
Potential for systemic 
and gastrointestinal 
events (fever, 
headache, myalgia,  
abdominal pain, 
anorexia,  nausea, 
vomiting,  vomiting, 
diarrhea, and  
malaise/fatigue) 
following  vaccination.  These systemic events are common  adverse 
reactions seen with other  vaccines, as noted in 
the FDA Center for Biologics Evaluation and 
Research  (CBER) guidelines on toxicity 
grading scales for healthy adult volunteers  
enrolled in preventive vaccine clinical  studies. 
Given the route of delivery and mechanism of 
action for an ingestible  vaccine,  some  
additional GI events may  
also be observed.  Actively monitor systemic 
and GI-associated reactions  
(solicited symptoms) for 7 
days following  each study  
drug administration.  
Potential for severe 
events of thrombosis in combination with 
thrombocytopenia 
(Thrombosis with 
thrombocytopenia 
syndrome, TTS), in 
some cases 
accompanied by 
[CONTACT_79602], as reported in 
rare cases following 
vaccination with two 
injected adenovirus -
vectored CO VID-[ADDRESS_137969] been reported 
following vaccination with two adenovirus -
vectored COVID-19 vaccines: the [COMPANY_008] COVID-19 vaccine (ChAdOx1; 
replication -deficient chimpanzee adenoviral 
vector ChAdOx1) and the Johnson and 
Johnson COVID-19 vaccine (Ad26.COV2.S; 
replication -incompetent adenovirus serotype 
26 vector). Reports include cases of 
thrombocytopenia in combination with arterial 
and venous thrombosis at unusual sites, such 
as cerebral venous sinus thrombosis (CVST) 
and splan chnic vein thrombosis, as well as 
more common sites such as veins of the lower extremity. Onset of symptoms associated with 
these AEs has typi[INVESTIGATOR_118472] [ADDRESS_137970] patho -
physiology of TTS is still under investigation. 
At this time, a mechanism related to the 
adenovirus vectors cannot be excluded.  Exclude enrollment of 
participants at hi gher risk of 
clotting events per review of medical history, physical 
exam and safety laboratory 
tests at screening. Actively 
monitor for signs and 
symptoms of 
thromboembolism and/or 
thrombocytopenia. Study 
participants should be 
instructed to seek 
immediat e medical 
attention if they develop 
symptoms including, but not limited to, shortness of 
breath, chest pain, leg pain and/or swelling, persistent 
abdominal pain, severe or 
persistent headaches, 
blurred vision or other 
vision changes, mental 
status changes or seizures, 
petechia, purpura beyond 
the site of vaccination, 
and/or easy bruising/ 
bleeding.  
VAXART  Protocol  Number:  VXA -NVV -[ADDRESS_137971]  
immune  responses.  
 
2.3.2.  Overall  Benefit/Risk  Conclusion 
Taking into account the measures to be utilized to minimize  risk to participants taking part in this  
study, the potential risks identified in association with the VXA -G1.1- NN vaccine for the 
prevention of norovirus infection are justified as by [CONTACT_122687] y stable adult participants.  
VAXART  Protocol  Number:  VXA -NVV -[ADDRESS_137972] 2021  Page 16 of 62  3.  OBJECTIVES AND ENDPOINTS  
 
Objectives  Endpoints  
Primary  
• To evaluate the immunogenicity of 
VXA-G1.1- NN with repeat -dose 
administration at Day [ADDRESS_137973] schedules (Week 4, [ADDRESS_137974] initial dose) in healthy adults aged 18- 55, inclusive  • VP1 specific IgA ASC by [CONTACT_28745]-linked 
immunospot (ELISpot)  
• Norovirus G1.1 histo-blood group antigen 
(HBGA)  blocking antibodies (BT50) 
• VP1 specific serum IgG by 
[CONTACT_122684] (MSD) assay  
 
Secondary   
• To assess the safety and tolerability of VXA- G1.[ADDRESS_137975] schedules (Week 4, 8 or 12) in healthy adults aged 18-55, inclusive • Frequency, duration, and severity of 
solicited symptoms of reactogenicity  
(local,  systemic)  for 1 week  following 
each dose of study drug 
• Frequency, duration, and severity of unsolicited serious AEs (SAEs), AEs of special interest (AESIs) and New Onset of Chronic Illness (NOCIs) through  each  Study 
Period ([ADDRESS_137976] each vaccination)  
Exploratory  
• To assess additional safety  
parameters  • Occurrence of clinically significant  
abnormalities in laboratory parameters  
(chemistry, hematology and urinalysis) at 1 week after each study drug dose and in vital signs immediately following each  dose 
• To assess long -term safety of VXA - 
G1.1-NN through [ADDRESS_137977] vaccination  • Frequency, duration, and  severity  of all  
SAEs , AESIs and NOCIs   through [ADDRESS_137978] vaccination  
• To assess additional immunogenicity  
parameters of VXA- G1.1 -NN • VP1 specific IgG ASC  
• VP1 specific serum  IgA 
• Ad5 neutralizing antibodies 
• VP1 specific IgG and  IgA memory B cells  
• B cell immunophenotypi[INVESTIGATOR_007] 
• Saliva  VP1  IgA 
• Nasal Swab VP1 IgA  (Note: Additional exploratory 
immunogenicity assays may also be  
performed to further evaluate the activity  of 
the VXA -G1.1 -NN vaccine  candidate)  
VAXART  Protocol  Number:  VXA -NVV -[ADDRESS_137979] -optimization study of an adenoviral - vector based oral norovirus 
vaccine (VXA -G1.1- NN) expressing GI.[ADDRESS_137980] 
vaccination dose (Week 8 for Cohort 1, Week 12 for Cohort 2 and Week 16 for Cohort 3), and 
a Follow -up period of [ADDRESS_137981] vaccination (Month 7 for Cohort 1, Month 8 for Cohort 2 
and Month 9  for Cohort 3 ). Study assessments will be conducted as shown in the SoA in 
Section 1.2 (Table 2) . In addition, participants will be contact[CONTACT_122688].  
After signing an informed consent, participants will undergo screening assessments to determine  
study eligibility over a 45 -day s creening per iod. 
On Day  1, participants  will be  enrolled sequentially in order of eligibility. Participants may be 
assigned to cohorts based on their availability for the second dose (boost). Cohorts [ADDRESS_137982] udy timeline. 
 
Group  Study  Drug  Dose  (IU ±0.5  log) Doses  Dosing  Schedule  Subjects  
Cohort 1  VXA -G1.1 -NN 1x1010 2 Day 1 & Week 4  10 
Cohort 2  VXA -G1.1 -NN 1x1010 2 Day 1 & Week 8  10 
Cohort 3  VXA -G1.1 -NN 1x1010 2 Day 1 & Week [ADDRESS_137983] a delayed second  dose  administered  within  1 week  of their original ly scheduled 
second -dose visit (+7 days  window). Participants  with a delayed second study drug 
administration will follow the delayed schedule through their  active period . 
All participants will enter the f ollow -up period 4 weeks after their second dose and will be 
monitored for SAEs, including AESI and NOCI, through End of Study. Participants will also be  
evaluated  for immunogenicity as specified in  the So A. 
Any participants who are not eligible to receive the second study drug administration will enter  
the follow -up period at that visit rather than receiving the second dose  and will be monitored 
for safety  and evaluated for immunogenicity through their End of Study as specified  in the 
SoA.  
VAXART  Protocol  Number:  VXA -NVV -[ADDRESS_137984]  2021   Page 18 of 62   
4.1. Scientific  Rational  for Study Design  
Emerging evidence generated in clinical settings with the [COMPANY_008] COVID -19 vaccine 
(AZD1222) indicates that a 12- week interval between vaccine doses might significantly 
improve efficacy and immunogenicity of AAV -based vaccination strategies compared to a 
shorter 4 - or 6-week dosing interval ( Voysey et al., 2021; Hung and Poland, 2021). In light of 
these findings, the current Phase 1b study is designed to assess the safety and immunogenicity 
of the VXA- G1.1- NN vaccine with a 2 -dose vaccination schedule using different repeat -dosing 
intervals (4, 8, or 12 weeks apart) in healthy young adults (18 to 55 years old).  
4.2. Justification  for Varying Dose Schedules 
Based on the safety results observed in completed and ongoing studies with prior vaccines  
utilizing the VAAST platform, the multiple dosing schedules  of VXA- G1.1 -NN selected for 
this Phase 1b  study are second dose at 4 weeks for Cohort 1, 8 weeks in Cohort 2 and 12 
weeks at Cohort 3, with participants receiving at 1x1010 IU± 0.[ADDRESS_137985] been  immunized  with  multiple  Vaxart  recombinant  adenovirus  serotype  
5 (rAd5) vaccine candidates at 1x1010 IU and a similar number of subjects have been immunized 
at 1x1011 IU. These dose levels demonstrated a favorable safety profile and generated strong 
immune responses. Repeat dosing with the VXA -G1.1- NN oral vaccine has previously been  
tested at doses up to 1x1011 IU at Days 1 and 29 in two prior trials (VXA -G11-101 and VXA-
G11-102). These studies showed the vaccine to be safe and immunogenic . The current  study will 
evaluate different dosing schedules of VXA- G1.[ADDRESS_137986] as follows: 
Study Period  Cohort 1  
(Day 1 and Week 4)  Cohort 2  
(Day 1 and Week  8)  Cohort 3  
(Day 1 and Week 12)  
Screening  Period:  45 days 45 days 45 days  
Study Period 1:  4 weeks (Day 1 –  Week 4)  4 weeks (Day 1 –  Week 4)  4 weeks (Day 1 –  Week 4)  
Study Period 2:  4 weeks (Week 4 –  8) 4 weeks (Week 8 –  12) 4 weeks (Week 12 –  16) 
Follow -Up Period:  [ADDRESS_137987] completed the study if they complete through the study 
Active and Follow -Up Period  for their Cohort.  
 
4.5.  Safety and Final Database Lock  
Following completion of the Active Period by [CONTACT_122689], the  database will be cleaned  and 
locked. The Clinical  Study  Report (CSR) will be written based on  the last Active Visit  dataset  
(Cohort 1-  Week 8; Cohort 2-  Week 12, Cohort 3 – Week 16) . 
Following completion of End of Study visit for all subjects, the safety database will be cleaned and 
locked and data collected during the Follow -Up Period will be amended to the Study CSR.  
VAXART  Protocol  Number:  VXA -NVV -[ADDRESS_137988]  meet  all the following:  
Age 
1. 18 to 55 years  old inclusive at  the time  of signing the Informed  Consent Form  (ICF).  
Type  of Participants  
2. General good health, without significant uncontrolled medical illness, based on medical 
history, physical examination, vital signs, and clinical laboratories (CBC, chemistry, and 
urinalysis) as determined by [CONTACT_122690] R esear ch M onitor and 
Sponsor  
3. Body mass index (BMI) between  17 and 35 kg/m2 at screening  
4. Available for all planned visits and phone calls, and willing to complete all protocol - 
defined procedures and assessments (including ability and willingness to swallow  
multiple small enteric- coated tablets  per study dose).  
Gender  and Reproductive  Considerations  
5. Male or  female  participants  
Contraception use by [CONTACT_122691]. Refer to Appendix 4 (Section 10.4)  
a. Female participants  must  provide  a negative  pregnancy test  at each required visit and 
fulfill one of the following criteria:  
• At least [ADDRESS_137989] -menopausal (defined as amenorrhea for ≥12 consecutive 
months prior to Screening without an alternative me dical cause).  
• Women under [ADDRESS_137990] -menopausal status via a 
follicle -stimulating hormone (FSH) test if another option to prevent potential 
pregnancy will not be utilized for [ADDRESS_137991] vaccination.  
• Surgically sterile  
• Use of oral, implantable, transdermal or injectable contraceptives for [ADDRESS_137992] be approved by [CONTACT_11856]  
• A reliable form of contraception must be approved by [CONTACT_737] (e.g., 
double barrier method, Depo- Provera, intrauterine device, Norplant, oral 
contraceptives, contraceptive patches).  
• Not be sexually active (abstinent) or be in a relationship with partner who is 
sterile (must be discussed with site staff and documented).  
Informed  Consent  
6. Capable of giving signed informed consent which includes compliance with the  requirements  
and restrictions listed  in the ICF  and in this protocol.  
VAXART  Protocol  Number:  VXA -NVV -[ADDRESS_137993] be excluded from participating in the study if they meet any of the  
following:  
 
Medical  Conditions  
1. Presence of significant uncontrolled medical or psychiatric illness (acute or chronic)  
including ins titution of new medical/surgical treatment or significant dose alteration for 
uncontrolled symptoms or drug toxicity within [ADDRESS_137994] 3 years (excluding basal cel l 
carcinoma  or squamous cell carcinoma)  
3. Presence of immunosuppression or medical condition possibly associated with impaired  
immune  responsiveness, including diabetes mellitus  [ADDRESS_137995] the distribution/safety evaluation of an orally administered  
vaccine targeting  the mucosa of the small intestine.  
Such  conditions may include  but are not  limited to:  
a. Esophageal  Motility  Disorder  
b. Malignancy  
c. Malabsorption  
d. Pancreaticobiliary  disorders  
e. Irritable  bowel  syndrome  
f. Inflammatory  Bowel  Disease  
g. Surgical  Resection  
h. GERD  
i. Hiatal  Hernia  
j. Peptic  Ulcer  
(History  of cholecystectomy  is not exclusionary)  
5. History  of any form of  angioedema  
6. History of serious reactions to any vaccination such as anaphylaxis, respi[INVESTIGATOR_43644], hives  or abdominal pain  
7. Diagnosed bleeding disorder or significant bruising or bleeding difficulties that could 
make  blood draws problematic  
8. Any condition that  resul ted in the absence or  removal  of the spleen  
9. Acute disease within 72 hours prior to vaccination defined as the presence of a moderate  
or severe illness (as determined by [CONTACT_122692]).  (Assessment  may be  repeated during screening  period.)  
10. Presence of a fever ≥ 38oC measured orally at baseline (Assessment may be repeated  
during screening  period)  
11. Any significant hospi[INVESTIGATOR_122663].  
12. Any other condition that in the clinical judgment of the investigator would jeopardize the  
VAXART  Protocol  Number:  VXA -NVV -[ADDRESS_137996]  2021   Page 21 of 62  safety or rights of a participant taking in the study, would render the participant unable to  
comply with  the protocol  or would interfere  with  the evaluation of  the study  endpoints  
Diagnostic  Assessments 
13. Positive human immunodeficiency virus (HIV), Hepatitis B surface antigen (HBsAg) or 
hepatitis  C virus (HCV) tests  at the screening  visit  
14. Positive  urine  drug screen for  drugs of  abuse at  screening  
15. Positive  breath or urine  alcohol  test at screening  and baseline  
Prior/Concurrent Therapy  
16. Receipt of a licensed vaccine within 14 days prior to baseline vaccination or planned 
administration  during the study active period  ([ADDRESS_137997] each study vaccination) . 
17. Use of antibiotics, proton pump inhibitors, H2 blockers or antacids within [ADDRESS_137998] the immune function (e.g., systemic corticosteroids  
and others) within 2 weeks before study drug administration or planned use during the  
active study period  
19. Daily use of nonsteroidal anti -inflammatory drugs within 7 days prior to study drug  
administration  or planned use duri ng the active study period  
20. Administration  of any investigational  vaccine,  drug  or device  within  8 weeks  preceding 
study drug administration  (Day 1) , or planned use within  the duration of  the study  
Other Exclusions 
21. Donation or use of blood or blood products within 30 days prior to study drug 
administration  or planned donation during the active study period   
22. History  of drug, alcohol  or chemical  abuse  within  1 year  of screening  
23. History of hypersensitivity or allergic reaction to any component of the in vestigational  
vaccine,  including but not limited to fish gelatin  
VAXART  Protocol  Number:  VXA -NVV -[ADDRESS_137999]  2021   Page 22 of 62  5.3.  Screen  Failures  
Screen failures are defined as participants who consent to participate in the clinical study but are 
not subsequently ent ered in the study. A minimal set of screen failure information is required to  
ensure transparent reporting of screen failure candidates to meet the Consolidated Standards of  
Reporting Trials (CONSORT) publishing requirements and to respond to queries from regulatory  
authoritie s. Minimal information includes demography, screen failure details, eligibility criteria,  
and any SAE.  
Re-screening/re -assessment outside the s creening period will be possible on a case -by-case basis 
following Sponsor approval. Participants allowed to be r e-screened will be assigned a new  
screening number; such participants will be determined a permanent screen failure after the 
second  screening  determines the participant is ineligible.  
VAXART  Protocol  Number:  VXA -NVV -[ADDRESS_138000] 2021  Page 23 of 62  6. STUDY DRUG, CONCOMI TANT THERAPY AND LIFE -STYLE  
CONSIDERATIONS  
Study drug is defined as any investigational intervention(s), marketed product(s), placebo, or 
medical device(s) intended to be administered to a study participant according to the study  
protocol. 
 
6.1.  Study  Dru g Administration  
VXA-G1.1- NN is an E1/E3 -deleted, replication -incompetent, Ad5 vaccine vectors designed for 
use as an oral vaccine. The monovalent vaccine vector encodes the full -length of VP1 gene of 
Norovirus GI.1. The adjuvant consists of a double-stranded RNA TLR3 agonist which enhances 
immune  induction to expressed antigen in the gut mucosa. 
Table  4 VXA-G1.1- NN Study  Drug  
 
Intervention Name  [CONTACT_122728] -G1.1 -NN 
Type  Biologic  
Dose  Formulation  Enteric -coated  tablets  
Unit Dose Strength(s)  6.7x109 IU per tablet  
(Drug Product Lot: DP -05.[ZIP_CODE])  
Dosage  Level(s)  1x1010 IU ± 0.5 log  
(2 tablets of VXA- G1.1 -NN ( Lot DP-05.[ZIP_CODE]) will be dispensed to 
deliver each dose)  
Route of Administration  Oral 
Administration 
instructions  Participants should fast and refrain from ingesting solid food for at least  
8 hours  prior to oral dosing. A trained member of the site study staff  
will dispense the tablet(s) constituting their assigned dose to the  
participant. The participants  will swallow the tablets  with 360 to  
480 mL of water or clear fruit juice (acidic, such as cranberry juice) 
followed by a light snack (e.g., crackers) at time of  dosage  administration  
to aid in tablet transit  out of the stomach.  Normal  food consumption may 
resume 90 minutes after dosing. For more  information refer to the Study  
Pharmacy Manual.  
Sourcing  Study drug will be provided to the site by [CONTACT_122693]. 
Packaging  and Labeling  The tablets are packaged into foil-sealed, high -density polyethylene  
(HDPE)  screw-cap containers with 10  tablets per  bottle. 
All packaging and labeling operations for study drug will be performed according to Good Manufacturing Practices (GMP) for Medicinal Products and the relevant regulatory requirements. Label text for the  
study drug bottle will at a minimum include name [CONTACT_122729],  
the protocol  number,  the name  [CONTACT_122730],  the lot number  of the 
VAXART  Protocol  Number:  VXA -NVV -[ADDRESS_138001], the concentration of the vaccine, the date of manufacturing or  
expi[INVESTIGATOR_1516].  
The final dispensing container (cup or secondary bottle)  will be 
appropriately labeled  with the participant’s  unique  identifier, the  
time/date of dose preparation within the pharmacy an d additional  
information as deemed necessary per the site’s standard operating  
procedures.  
Storage  Condition  VXA- G1.1 -NN vaccine tablets will be stored at 2 to     8°C at the 
clinical site until ready for use. Tablets should not be frozen. Do not 
use and contact [CONTACT_122694].  
 
6.2.  Compliance of Study D rug 
Participants will receive study drug directly from the investigator or designee, under medical 
supervision. The date and time of each dose administered in the clinic will be recorded in the source documents and recorded in the eCRF. The study drug and study participant identification will be confirmed at the time of dosing by a member of the study site staff other 
than the person administering the study drug. 
 
6.2.1 Dose Adjustments/Modifications/Delays  
Dose  adjustments and  or modifications  are not planned or allowed  under this clinical  protocol. 
All participants  should receive the full  dose of 1x10
10 IU ±  0.5 log at the protocol -defined study 
visits by [CONTACT_122695]. Any modification from this 
schedule or planned dose should be recorded  as a protocol violation and reported to the Sponsor (or  
designee). 
 
6.3. Handling  and Accountability  
1. The investigator or designee must confirm appropriate temperature conditions have been 
maintained during transit for study drug received and any discrepancies are reported and  
resolved  before use of study drug. 
2. Only participants enrolled in the study may receive study drug and only authorized site 
staff may supply or administer study drug. All bottles of study drug must be stored in a 
secure, environmentally controlled, and monitored (manual or automated) area in accordance with the labeled storage conditions with access limit ed to the investigator and 
authorized site  staff.  
3. The investigator,  institution, or the head  of the medical  institution  (where  applicable)  is 
responsible for study drug accountability, reconciliat ion, and record maintenance (i.e., 
receipt,  reconciliation, and final disposition records).  
4. At the end of the study active period, the monitor will conduct a final drug  
reconciliation  for all  participants  and the study site  overall.  All records of study drug 
VAXART  Protocol  Number:  VXA -NVV -[ADDRESS_138002]  2021   Page 25 of 62  administration, accountabil ity records and study drug disposition records will be  
examined and reconciled by [CONTACT_11200]. Further details will be provided in the  
Study Pharmacy Manual.  
Further  guidance  and information  for the final  disposition  of unused study drug are provided  in 
the Pharmacy Manual.  
 
6.4. Treatment  of Overdose  
Any overdose of study drug should be recorded in the eCRF (including quantity of the excess  
dose and the duration of the overdose). AEs associated with an overdose or incorrect  
administration of study drug should be recorded in the AE eCRF. An overdose will not be  
considered  an SAE  unless the  outcome  of the overdose  meets  seriousness  criteria.  
There  is no specific management  of an overdose  of VXA- G1.[ADDRESS_138003] dose  
administration (completion of Active Study period) must be recorded onto the eCRF from the  
participant’s  medical file  along with:  
• Reason for use 
• Dates of  administration  including start  and end dates  
• Dosage information  including dose  and frequency 
Medications for pre -existing medical conditions or required for a medical condition during the  
study are allowed if not considered exclusionary.  
The Sponsor's Medical Monitor (or designee) should be contact[INVESTIGATOR_530] i f there are any questions 
regard ing concomitant  or prior  therapy. 
 
6.5.1. Prohibited Concomitant Medication  
Medications specifically prohibited in the exclusion criteria are not allowed during the Active  
Study period (Section 5.2 prior/concurrent therapy), unless deemed medically necessary by [CONTACT_122696].  
 
6.6.  Intervention  after  the End of  the Study  
No additional  intervention  is planned beyond the  end of  the study.  
 
7. DISCONTINUATION OF STUDY  DRUG  AND  
PARTICIPANT  WITHDRAWAL  FROM STUDY  
 
7.1.  Discontinuation  of Study  Drug  
In some instances, it may be necessary for a participant to permanently discontinue study drug 
(that is, not receive the second vaccination ).  
VAXART  Protocol  Number:  VXA -NVV -[ADDRESS_138004]  2021   Page 26 of 62  Permanent discontinuation of study drug does not mean withdrawal from the study, and the  
participant will be encouraged to remain in the study and continue to complete all study follow - 
up visits.  
Participants  may discontinue  or be discontinued from  study drug  at any time.  A participant  may 
discontinue  study drug for reasons including but not limited to:  
• Adverse event  
• Death  
• Lost to follow -up 
• Physician  decision  
• Protocol  deviation 
• Study terminated  by [CONTACT_2728]  
• Withdrawal by [CONTACT_3445] (only for discontinuing study drug, but will remain in 
study)  
The reason  for participant discontinuation  from study drug will  be recorded  in the eCRF.  
 
7.2. Early Termination Visit (Active or Follow -Up Period)  
If a participant is removed from the study or declines further participation during the study 
Active Period, the Early Termination (ET) visit should be the next visit completed as shown in 
the SoA per Cohort Assignment . Participants will enter the follow -up period to be monitored 
for safety and immunogenicity even if they discontinue study drug prematurely unless they 
withdraw consent.  
If a subject withdraws from the study after entering the f ollow -up period ( i.e., after completed 
their Active Phase partici pation) the subject will be called for final assessments, per the End of 
Study Visit assessments as outlined in the SoA ( 0). 
 7.3. Participant  Withdr awal  from  the Study  
Participants hav e the right to withdraw from the study at any time and for any reason without  
prejudice to their future medical care by [CONTACT_122697]. A participant may  
withdraw  from  the study for reasons including but not limited to:  
• Death  
• Withdrawal  by [CONTACT_3445]  
• Lost to follow -up 
• Study terminated  by [CONTACT_122698].  
At the time of withdrawal from the study, the ET  visit should be completed, as  shown in the SoA  
(Table  2). 
If the  participant  withdraws  consent  for disclosure  of future  information,  the Sponsor  may retain  
and continue to use  any data collected  before such  a withdrawal of consent. 
If a participant withdraws from the study, he/ she may submit a written request of destruction 
VAXART  Protocol  Number:  VXA -NVV -[ADDRESS_138005] be taken if a participant fails to return to the clinic for a required  
study visit:  
• The site must attempt to contact [CONTACT_122699]/or  
should continue in the study. Consultation with the Sponsor is required if the new 
visit date is more than 7 days during each Cohort’s Active Period.  
• Before a participant is deemed lost to follow -up, the investigator or designee must  
make every effort to regain contact [CONTACT_6635] (where possible, telephone  
calls and, if necessary, a certified letter to the participant’s last known mailing  
address or local equivalent methods). These contact [CONTACT_122700]’s medical recor d. 
• Should the participant continue to be unreachable, he/she will be considered to have  
withdrawn from  the study.  
VAXART  Protocol  Number:  VXA -NVV -[ADDRESS_138006]  2021   Page 28 of 62  8. STUDY  ASSESSMENTS AND  PROCEDURES  
• Study procedures and their timing are summarized in the SoA (Table 2). Protocol  
waivers or exemptions are not allowed. 
• Immediate safety concerns should be discussed with the Sponsor immediately upon 
occurrence or awareness to determine if the participant should continue or  
discontinue  study intervention.  
• Adherence to the study design requirements, including those specified in the SoA is  
essential  and required for  study conduct.  
• All screening evaluations must be completed and reviewed to confirm that potential 
participants  meet all eligibility  criteria.  The investigator  will maintain  a screening  log 
to record details of all participants screened and to confirm eligibility or record  
reasons for screening  failure, as applicable.  
• Participants who experience any serious or severe AEs or any event of  concern 
should be instructed to contact [CONTACT_122701] a visit for  further 
evaluation. If an unscheduled visit occurs, the reason for the visit and data  collected  
during the  visit should be recorded and  entered into the unscheduled eCRF. 
 
8.1. Immunogenicity  Assessments  
Immunogenicity will be evaluated using cellular and humoral immune function assays from  
blood and mucosal (saliva and nasal swab) samples. Samples will be collected from all  
participants according to the time points specified in the SoA. The following analytes will be  
measured:  
Key Immunogenicity assessments:  
• VP1 specific IgA  ASC by [CONTACT_34536]  
• HBGA blocking antibodies  by [CONTACT_122702]50 
• VP1 specific serum IgG MSD assay Exploratory  Immunogeni city 
assessments:  
• VP1 specific IgG  ASC  
• VP1 specific serum  IgA 
• Ad5 neutralizing antibodies  
• VP1 specific IgG and  IgA memory B cells  
• B cell immunophenotypi[INVESTIGATOR_007] 
• Saliva  VP1  IgA 
• Nasal  VP1  IgA 
Additional exploratory immunogenicity assays may also be performed to further evaluate the  
activity of the VXA -G1.1 -NN vaccine candidate. Note that not all sample timepoints may be  
relevant  for some  of the  analysis,  so not all  assays may  be performed at  all timepoints.  
Sample collection, processing and shippi[INVESTIGATOR_122664]. 
VAXART  Protocol  Number:  VXA -NVV -[ADDRESS_138007] udy drug dose, unsolicited AEs for 4 weeks  
following  each study drug  dose, SAEs  (including AESIs  and NOCIs)  for [ADDRESS_138008] study drug dose. T he occurrence of these events should be reported to the Sponsor in a n 
expedited manner, similarly to SAEs as described in Table 9 . AESIs are  listed  in Appendix 5 
(Section  10.5).  
Planned time  points  for all safety  assessments are  provided in the SoA  (Table  2). 
 
8.2.1 Physical Examination  
A complete physical examination will include, at a minimum, assessments of the skin,  
cardiovascular system, respi[INVESTIGATOR_2133], abdomen (gastrointestinal, l iver and spleen) and  
neurological  system.  Height  and weight  will also be measured  and recorded  at Screening.  
A targeted,  symptom -directed  physical  examination will include,  at a minimum,  assessments of  
the skin, respi[INVESTIGATOR_36517], cardiovascular  system,  and abdomen (liver  and spleen)  will be 
measured at site visits as specified in the SoA . 
 
8.3 Vital Signs  
Blood pressure, oral temperature,  heart rate, and respi[INVESTIGATOR_122665] 5 minutes. Vital signs will be measured prior to any blood 
draw that occurs at the  same  timepoint.  
 
8.3.1.  Clinical Safety  Laboratory Assessments 
• See Appendix 2 (Section 10.2) for the list of clinical laboratory tests to be performed 
and the SoA for the timing and frequency. 
• The investigator must review the laboratory report, document this review, and record  
any clinically relevant changes occurring during the study in the AE section of the  
eCRF.  The la boratory  reports must be filed  with the  source documents.  
• All laboratory tests with values considered clinically significant during participation  
in the study or within [ADDRESS_138009] dose of study drug should be repeated 
until the values return to  normal or baseline or are no longer considered clinically 
significant by [CONTACT_9304]’s Medical Monitor (or designee). If such  
values do not return to normal/baseline with in a period of time judged reasonable by 
[CONTACT_093],  the etiolo gy should be identified, and the  Sponsor  notified. 
• Laboratory values which are abnormal AND lead to either the requirement for an  
intervention, the requirement for additional medications,  or are felt to otherwise be  
medically  important  should be  recorded  as adverse events in the  eCRF.  
• Hematology or serum chemistry parameters will be graded according to the FDA  
toxicity grading scale (Section [IP_ADDRESS].2) and will be adjusted according to local  
laboratory reference ran ges. Participants have the ability to rescreen once should  
screening values fall outside of the allowed eligibility criteria, per the discretion of the Investigator.  
 
VAXART  Protocol  Number:  VXA -NVV -[ADDRESS_138010]  2021   Page 30 of 62   
 
8.4.  Adverse Events  and Serious  Adverse Events  
The definitions of a ny AE (solicited and unsolicited), SAE and AESIs/NOCIs can be 
found in Appendix 3 (Section 10.3 ). 
The investigator and any qualified designees are responsible for detecting, documenting, and 
recording events that meet the definition of a ny AE (solicited and unsolicited), or SAE.  
Investigators remain responsible for following up AEs, SAEs and other reportable  safety  events 
for outcome.  
 
8.4.1.  Time Period and Frequency for Collecting AE, SAE and Other  Reportable  Safety  
Event  Information  
All AEs (solicited and unsolicited), SAEs and other reportable safety events that occur after the 
consent form is signed but before study administration must be reported by [CONTACT_122703] a  protocol -
specified intervention, including but not limited to washout or discontinuation of usual  therapy, 
diet, or  a procedure.  
 
Table  5 below  summarizes the  different  reporting  timelines  for AEs  (unsolicited  and 
solicited),  SAEs,  S[LOCATION_003]R and pregnancy. 
Medical occurrences that begin before the start of study drug but after obtaining informed 
consent  will be recorded  on the  Medical  History/Current Medical  Conditions  section  of the 
eCRF  not the AE  section.  
All SAEs will be recorded and reported to the Sponsor or designee immediately and under no 
circumstance should this exceed 24 hours, as indicated in Appendix 3 (Table 17) . The  
investigator will submit any updated SAE da ta to the Sponsor within [ADDRESS_138011] 2021   Page 31 of 62  VAXART  Protocol Number:  VXA- NVV-105 
 
Table 5  Adverse Event  Reporting  Timelines  to the Sponsor  
 
Type of Event AE (unsolicited) AE (solicited)  SAE  / AESI /  NOCI  Pregnancy  
Reporting  period  From first dose until [ADDRESS_138012] dose until  end of 
Follow -Up Period/ EOS From first dose until  end of 
Follow -Up Period/ EOS 
Reporting Timelines to the  
Sponsor  Entered into the clinical database on an ongoing  
basis  Entered into the  
clinical database on an  
ongoing basis Within  24 hours  Within  24 hours  
Reporting  
Method  AE eCRF  Solicited Symptom  
Diary  AE eCRF or  SAER  
Form Pregnancy  form  
AE, Adverse event ; SAE, Serious adverse event ; S[LOCATION_003]R, serious unexpected suspected adverse reaction .
VAXART  Protocol  Number:  VXA -NVV -[ADDRESS_138013]  2021   Page 32 of 62  8.4.2. Method  of Detecting  AEs  and SAEs   
Appendix 3 (Section 10.3) provides the method of recording (Table 10), evaluating 
severity  (Table  11), and assessing  causality  (Table  16) of AEs  and SAEs  and the  
procedures for completing and transmitting SAE reports (Table 17).  
Care will be taken not to introduce bias when detecting AEs or SAEs. Open- ended and non-
leading questioning of  participants  is the preferred  method to inquire  for AE occurrences.  
 
8.4.3. Follow -Up of AEs  and SAEs  
The investigator is obligated to perform or arrange for the conduct of supplemental 
measurements and evaluations as medically indicated to elucidate the nature and causality of the 
AE or SAE as fully as possible. This may include laboratory tests or investigations, histopathological  exami nations, or  consultation with  other  
health care professionals . 
The investigator will submit updated SAE data to Sponsor within 24 hours of receipt of the  
information.  AEs  and pregnancy will  be followed  by [CONTACT_122704] 4. 
 
8.4.4.  Regulatory Reporting  Requirements for SAEs  
• Prompt notification by [CONTACT_29532] a SAE is essential so that legal 
obligations and ethical responsibilities towards the safety of participants and the  safety  of 
the study drug  under clinical investigation are  met.  
• The Sponsor  has a legal  responsibility  to notify both  the local  regulatory  authority  and other 
regulatory agencies about the safety of the study drug under clinical  investi gation. The  
Sponsor  will comply with  country- specific regulatory requirements  relating to safety 
reporting to the regulatory authority, Institutional Review Boards  (IRB)  and inves tigators.  
• Investigator safety reports must be prepared for S[LOCATION_003]R according to local regulatory  
requirements and Sponsor  policy and  forwarded  to investigators  as necessary.  
• An investigator who receives an investigator safety report describing a SAE or other  
specific safety information (e.g., summary or listing of SAEs) from the Sponsor will  
review and then file it along with the IB and will notify the IRB, if appropriate,  according  
to local  requirements.  
 
8.4.5.  Death  Events  
Events resulting in death will be  an SAE regardless of association to study drug. Death is an 
outcome and should not be reported as an event term. The event that leads to the death should be  
reported as the SAE term.  
 
8.4.6.  Pregnancy  
• Details of  all pregnancies  in female  partners  of male  participants  will be collected  as 
outlined  in Appendix 4 (Section 10.4).  
• If a pregnancy is reported, the investigator should inform the Sponsor within 24 hours  
of learning of the pregnancy and should follow the procedures outlined in Appendix 4  
(Section  10.4.3) . 
VAXART  Protocol  Number:  VXA -NVV -[ADDRESS_138014]  2021   Page 33 of 62  9. STATISTICAL  CONSIDERATIONS  
 
9.1. Sample  Size  Determination  
The sample size was determined based on experience of a typi[INVESTIGATOR_122666] 1 vaccine study,  
therefore there are no sample size calculations utilized for this study.  Thirty  subjects ( 30) will be 
enrolled in each cohort arm for a total planned enrollment of 30 subjects. The numbers of  
participants  per scheduling group are  predicted  to yield  meaningful  safety  and immunogenicity 
resul ts in order to plan for future clinical trials.  
In previous human studies with Ad5 vectored oral tableted vaccines using the same vaccine  
platform (Ad5 vectored vaccine coding for target virus -specific antigens and  dsDNA adjuvant), 
the vaccine  was well  tolerated  at total doses  up to 2x1011 IU. 
In this study we will observe the difference in IgA ASC responses of  VXA- G1.1- NN given at 
multiple schedul ed timepoints . In a prior Phase  1 study, for  VXA- GI.1- NN at a dose of 1011 IU 
(N=23), the average IgA ASC count was [ADDRESS_138015] deviation (SD) of 
740. Under the current protocol, immune responses with the initial  vaccination at Day [ADDRESS_138016]  vaccination . 
Populations  for Analyses  
 
Analysis  Population Description  
Screened  All subjects who  enter  screening  (assigned  a screening  number)  
Dose [ADDRESS_138017] 1 dose of the study drug.  
 
9.2. Statistical Analyses  
The statistical analysis plan (SAP) will be developed and finalized before database lock for any 
of the planned analyses. It will describe the participant populations to be included in the analyses  
and the  procedures  for accounting for missing,  unused, and spurious  data.  This  section  provides  a 
summ ary of the planned statistical analyses of the primary, secondary, and tertiary/exploratory  
endpoints.  
VAXART  Protocol  Number:  VXA -NVV -[ADDRESS_138018]  2021  Page 34 of 62  9.2.1. Safety  Analysis 
Safety will be summarized for each cohort:  
Cohort 1: ([ADDRESS_138019] vaccination) 10 subjects will receive two doses of 1x1010 IU± 0.5 log at 
Day 1 and Week 4 
Cohort 2: (8-week boost vaccination) 10 subjects will receive two doses of 1x1010 IU± 0.5 log at 
Day 1 and Week 8 
Cohort 3: (12-week boost vaccination) 10 subjects will receive two doses of 1x1010 IU± 0.5 log 
at Day 1 and Week 12  
 
Solicited symptoms of reactogenicity, unsolicited AEs, SAEs, clinical laboratory  (blood 
chemistry, hematology, and urinalysis) test results, physical examination, and vital signs  will 
be summarized descript ively by [CONTACT_15449]. 
All analyses will be performed separately for each cohort. 
 
Endpoint  Statistical  Analysis  Methods  
Primary  
(measured from  
Day 1 through  
end of Active 
Period) VP1 specific IgA ASC by [CONTACT_28745]-linked  immunospot  (ELISpot)  
Norovirus G1.1 histo-blood group antigen (HBGA)  blocking antibodies  (BT50) 
VP1 specific serum IgG by [CONTACT_122705] (MSD) assay  
Descriptive statistics will be provided for each reactogenicity endpoint for each dose  
and treatment group. Local reactions and systemic events from Day 1 through Day 8  
after each dose will be presented by [CONTACT_122706].  
Descriptive summary statistics will include counts and percentages of participants 
with the indicated endpoi nt. 
  Secondary  
(measured from  
Day 1 through  
end of Active 
Period) Frequency, duration, and severity of  solicited symptoms of reactogenicity  
(local,  systemic) for 1 week  following   each dose of  study drug  
Frequency, duration, and severity of  unsolicited adverse  events (AEs)  and serious 
AEs (SAEs) through   each Study P eriod ([ADDRESS_138020] each vaccination ) 
AEs will be categorized according to the Medical Dictionary for Regulatory 
Activities (MedDRA) terms. Descriptive summary statistics (counts and 
percentages) will be provided for any AEs for each  vaccine group. SAEs will be 
categorized according to  MedDRA terms. The safety analyses are based on the 
safety population. Participants will be summarized by [CONTACT_9084]. Missing reactogenicity diary  data will not be imputed; missing  AE dates will be handled 
according to the  rules determined  in the SAP.  
  Exploratory  
 Occurrence of clinically significant  abnormalities in laboratory parameters 
(chemistry, hemat ology and urinalysis) at [ADDRESS_138021] ry 
laboratory values at each time point as appropriate for each cohort, including 
grading shifts in hematology and chemistry laboratory assessments between 
baseline and each subsequent measurement. Descriptive summary  statistics will 
include counts and per centages of participants with the indicated  endpoint.  
VAXART  Protocol  Number:  VXA -NVV -[ADDRESS_138022] was 
assigned . 
Immunogenicity samples will be drawn for all participants. Immunogenicity analyses will be  
based upon results from appropriately sized subsets of samples, according to the purpose. The 
statistical analysis of immunogenicity results will be primarily based on the evaluable immunogenicity populations. An additional analysis will be performed based on the all- available 
populations if there is a large enough difference in sample size between the all -available  
immunogenicity  population and the evaluable immunogenicity population. 
Immunogenicity will be summarized for each cohort: 
Cohort 1: ([ADDRESS_138023] vaccination) 10 subjects will receive two doses of 1x1010 IU± 0.5 log at 
Day 1 and Week 4 
Cohort 2: (8-week boost vaccination) 10 subjects will receive two doses of 1x1010 IU± 0.5 log at 
Day 1 and Week 8 
Cohort 3: (12-week boost vaccination) 10 subjects will receive two doses of 1x1010 IU± 0.5 log 
at Day 1 and Week 12  
 
Endpoint Statistical Analysis  Methods  
Exploratory 
(Key  
Immunogenicity 
Endpoints)  VP1 specific IgG ASC  
VP1 specific serum  IgA 
Ad5 neutralizing antibodies 
VP1 specific IgG and  IgA memory B cells  
B cell immunophenotypi[INVESTIGATOR_122667]1  IgA 
Nasal Swab VP1 IgA  
All measures will be summarized descriptively for each cohort, for all 
timepoints where measured. The Dose 1 and Dose 2 evaluable 
immunogenicity populations  will be used for these analyses.  
 
 
 
VAXART  Protocol  Number:  VXA -NVV -[ADDRESS_138024]  2021   Page 36 of 62  9.3. Safety Oversight 
9.3.1. Internal  Sponsor  Review  
Safety data will be monitored on an ongoing basis by [CONTACT_093] (or medically qualified  
designee) and the Sponsor’s Medical Monitor (or designee) in order to promptly identify and flag 
any event  that potentially  raises concern regarding  a participant’s safety . 
The Medical Monitor will be a physician experienced in the conduct of res earch clinical  studies  
whose  primary  responsibility  will be to monitor  participant  safety.  The Medical  Monitor  will be 
responsible for reviewing the cumulative safety data, including a review of safety  laboratory 
test results and adverse event reporting. The Medical Monitor will be become and familiar with 
study- specific data as well as relevant background information about the disease, 
investigational drug, and target population under study. The Medical Monitor(s) will be  
empowered to request a  safety review which can suspend the study, recommend amendments to 
the protocol, and/or to request further information.  
 
10. SUPPORTING DOCUMENTATION AND OPERATIONAL  
CONSIDERATIONS  
10.1. Appendix 1: Regulatory,  Ethical,  and Study Oversight 
Considerations  
10.1.1. Regulatory and Ethical Considerations  
• This study will be  conducted in  accordance with  the protocol  and with  the following:  
Consensus ethical principles derived from international guidelines including the Declaration of  
Helsinki and Council for International Organizations of Medical Sciences (CIOMS) International  
Ethical Guidelines  
Applicable  ICH  Good Clinical Practice (GCP)  Guidelines  
Applicable  laws and  regulations  
• The protocol, protocol amendments, ICF, Investigator Brochure, and other relevan t 
documents (e.g., advertisements) must be submitted to an IRB/IEC by [CONTACT_122707]/IEC  before the  study  is initiated.  
• Any amendments to the protocol will require IRB/IEC approval before  
implementation of changes made to the study design, except for changes necessary to  
eliminate  an immediate hazard  to study participants.  
• Protocols and any substantial amendments to the protocol will require health  
authority approval prior to initiation except for changes ne cessary to eliminate an  
immediate  hazard  to study participants. 
• The investigator  will be responsible  for the following:  
Providing written summaries of the status of the study to the IRB/IEC annually or more  
frequently in accordance with the requirements, policies, and procedures established by [CONTACT_91161]/IEC . 
Notifying the IRB/IEC of SAEs or other significant safety findings as required by [CONTACT_1744]/IEC  
procedures . 
VAXART  Protocol  Number:  VXA -NVV -[ADDRESS_138025] of the study at the site and adherence to requirements of 21 
CFR, ICH guidelines, the IRB/IEC, European regulation 536/ 2014 for clinical studies (if  
applicable), European Medical Device Regulation 2017/745 for clinical device research (if  
applicable), and all other applicable local regulations  
 
10.1.2. Financial  Disclosure  
Investigators and sub- investigators will provide the Spons or with sufficient, accurate financial 
information as requested to allow the S ponsor to submit complete and accurate financial  
certification or disclosure statements to the appropriate regulatory authorities. Investigators are  
responsible for providing inf ormation on financial interests during the course of the study and for  
1 year after completion of the study.  
 
10.1.3. Informed  Consent  Process  
• The investigator or his/her representa tive will explain the nature of the study to the  
participant  and answer  all questions  regarding the study.  
• Participants  must  be informed  that their participation  is voluntary. Participants  will be 
required to sign a statement of informed consent that meets  the requirements of [ADDRESS_138026] (HIPAA) requirements, where applicable, and the IRB/IEC or 
study center.  
• The medical record must include a statement that written informed consent was  
obtained before the participant was enrolled in the study and the date the written  
consent was obtained. The authorized person obtaining the informed consent must  
also sign the ICF.  
• Participants must be re -consented to the most current  version of the ICF(s) during  
their participation  in the study.  
• A copy of the  ICF(s)  must be  provided  to the  participant.  
A participant who is rescreened is not required to sign another ICF if the rescreening occurs  
within  30 days from  the previous  ICF signature  [CONTACT_568].  
 
10.1.4. Exclusion  of Women, Minorities,  and Children (Special  Populations)  
This clinical study will include women and men who are 18- 55 years of age, inclusive, and 
volunteers of all races and ethnicities who meet the inclusion/exclusion criteria, regardless of  
religion, sex, or ethnic background.  
 
10.1.5. Data Protection  
• Participants will be assigned a unique identifier by [CONTACT_941] S ponsor. Any participant  
records or datasets that are transferred to the S ponsor will contain the identifier 
only;  participant names or any information which would make the participant 
identifiable  will not be transferred.  
• The participant must be informed that his/her personal stu dy-related data will be used  
by [CONTACT_941] S ponsor in accordance with local data protection law. The level of disclosure  
must also be explained to the participant who will be requir ed to give consent for  
their data to be used as described in the informed consent.  
VAXART  Protocol  Number:  VXA -NVV -[ADDRESS_138027]  2021   Page 38 of 62  • The participant must be informed that his/her medical records may be examined by  
[CONTACT_122708], by [CONTACT_6667]/IEC members, and by [CONTACT_9326].  
10.1.6. Dissemination  of Clinical Study  Data  
A clinical study report will be developed by [CONTACT_9327]. This  
report will be an integrated clinical and stat istical report prepared according to the ICH E3  
guidelines.  
Sponsor will register the study and post study results regardless of outcome on a publicly 
accessible website in accordance  with the  applicable laws and  regulations.  
10.1.7. Data  Quality  Assurance 
All participant data relating to the study will be recorded on printed or  eCRFs unless transmitted  
to the Sponsor or designee electronically (e.g., laboratory data). The Investigator is responsible  
for verifying that data entries are accurate and  correct by [CONTACT_122709].  
The Investigator must maintain attributable, legible, contemporaneous, original, accurate, and 
complete  documentation (source  data) that supports the  information entered  in the  eCRF.  
The Investigator must permit study -related monitoring, audits, IRB/IEC review , and regulatory 
agency  inspections and provide direct  access to source data  documents.  
Details describing monitoring strategy (e.g., risk- based initiatives in operations and quality such 
as risk management and mitigation strategies and analytical risk -based monitoring), methods, 
responsibilities and requirements, including handling of noncompliance issues and monitoring 
techniques  (central,  remote,  or on- site monitoring)  are provided in  the Monitoring Plan.  
The Sponsor or designee is res ponsible for the data management of this study including quality 
review  of the data.  
The Sponsor maintains ultimate responsibility for the quality and integrity of study data, even if  
study- related duties and functions are transferred to other individuals or organizations (e.g., 
contractors  or contract  research organizations).  
Study monitors will perform ongoing source data verification to confirm that data entered into  
the CRF by [CONTACT_122710], legible, contemporaneous, origina l, 
accurate, and complete from source documents; that the safety and rights of participants are 
being protected; and that the study is being conducted in accordance with the currently approved 
protocol  and any other  study agreements,  ICH GCP,  and applicabl e regulatory requirements.  
Records and documents, including signed ICFs, pertaining to the conduct of this study must be  
retained by [CONTACT_9329] -GCP and local regulations or institutional policies. No 
records may be destroyed during the retent ion period without the written approval of the  
Sponsor. No records may be transferred to another location or party without written notification  
to the Sponsor. 
10.1.8. Source  Documents  
Source  documents  provide  evidence  for the existence of  the participant  and substantiate the  
integrity of the data collected. Source documents should be generated utilizing good 
documentation practices and  are filed  at the Investigator’s  site.  
VAXART  Protocol  Number:  VXA -NVV -[ADDRESS_138028]  2021   Page 39 of 62  Source documents are original documents, data, and records from which the participant’s eCRF  
data are obtained. These include but are not limited to hospi[INVESTIGATOR_1097], clinical and office charts, 
laboratory  and pharmacy records, diaries, microfiches, radiographs, and correspondence. 
Data entered in the eCRF that are transcribed from source documents must be consistent with the  
source documents or the discrepancies must be explained. The Investigator may need to request  
previous medical records or transfer records, depending on the study. Also, current medical  
records  must be available.  
The investigator  must  maintain  accurate documentation (source data)  that supports  the 
information  entered in the eCRF.  
Study monitors will perform ongoing source data verific ation to confirm that data entered into  
the eCRF by [CONTACT_1191], complete, and verifiable from source documents; that the safety and rights of participants are being protected; and that the study is  
being conducted in accordance with the currently approved protocol and any other s tudy 
agreements,  ICH GCP, and all applicable regulatory requirements.  
10.1.9. Publication  Policy  
The Sponsor will comply with the requirements for publication of study results. In 
accordance with standard editorial and ethical practice, the Sponsor will generally support 
publication of  multicenter studies only in their entirety and not as individual site data. In this 
case, a coordinating investigator [INVESTIGATOR_12992]. Requests for publication of site -specific data should be presented to the S ponsor for review and approval at 
least 90 days  prior  to submission for publication.  
10.2. Appendix 2: Safety Clinical Laboratory  Tests  
• The tests detailed in Table 6 will b e performed by [CONTACT_12082], unless  
otherwise  specified.  
• All safety laboratory samples including hematology, serum chemistry and serology are to be drawn by [CONTACT_122711], into the site prescribed appropriate tubes for the specific  tests and amounts prescribed by [CONTACT_12117].  
Refer to the laboratory manual for further details on specimen collection and handling procedures.  
• Protocol -specific requirements for inclusion or exclusion of participant are detailed in  
Section 5.  
• Additional tests may be performed at any time during the study as determined 
necessary  by [CONTACT_122712].  
• Investigators  must  document  their review  of each laboratory  safety  report.  
 
 
 
  
 
VAXART  Protocol  Number:  VXA -NVV -[ADDRESS_138029]  2021   Page 40 of 62  Table 6  Protocol -Required  Safety  Laboratory Assessments  
Hematology  Hemoglobin, lymphocytes, hematocrit, neutrophils, eosinophils, platelet  
count,  and complete white blood  cell count  
Serum  Chemistry  Alanine aminotransferase (ALT), alkaline phosphatase (ALP), aspartate  
aminotransferase (AST), total bilirubin, BUN, CPK, creatinine, random  
glucose,  calcium,  potassium,  sodium,  phosphorous,  albumin,  magnesium,  
amylase and total protein  
Urinalysis  Protein,  glucose  ketones,  bilirubin,  urobilinogen,  hemoglobin,  pH, specific  
gravity,  appearance, color, leukocyte  esterase, nitrite  
Urine drug screen  Amphetamines, methamphetamines, methadone, barbiturates,  
benzodiazepi[INVESTIGATOR_1651], cocaine, opi[INVESTIGATOR_858], methylenedioxymethamphetamine,  
phencyclidine,  tetrahydrocannabinol  
Other laboratory  
assessments  Hepatitis  B surface antigen,  hepatitis  C virus  antibody,  and human  
immunodeficiency virus  antibody types  1 and 2 (Screening  only)  
Female participants  of child -bearing  potential: urine  or serum  pregnancy tests 
 
VAXART  Protocol  Number:  VXA -NVV -[ADDRESS_138030]  2021   Page 41 of 62  10.3. Appendix 3: Adverse Events: Definitions and Procedures for  
Recording,  Evaluating, Follow -Up, and Reporting  
Table 7  Definition  of AE (Unsolicited  and Solicited)  
 
AE Definition 
• An AE is any untoward medical  occurrence in a clinical  study participant,  temporally  associated  
with the use of study intervention, whether or not considered related to the study intervention,  
occurring after first dose of study drug.  
• NOTE: A n AE can therefore be any unfavorable and unintended sign (including an abnormal  
laboratory finding),  symptom,  or disease (new or exacerbated)  temporally  associated  with the use 
of study intervention.  
Definition of Unsolicited and Solicited AE  
• Unsolicited AEs are any AEs reported spontaneously by [CONTACT_2299], observed by [CONTACT_122713]. Unsolicited AEs (all AEs not collected in the Solicited Sym ptom  Diary during the 
first week following each study drug administration) will be monitored and collected from the 
time of each dose through [ADDRESS_138031] each dose.   
• Solicited AEs are predefined systemic signs and symptoms of reactogenicity for which the  
participant is specifically questioned, and which are noted by [CONTACT_122714], including: 
 fever  (any temperature  100°F  or higher)  
 headache  
 myalgia  (muscle pain)  
 abdominal  pain 
 anore xia (defined and not eating)  
 nausea  
 vomiting  
 diarrhea  
 malaise/fatigue  
Participants will utilize a Solicited Symptom Diary issued on the day of each study drug  
administration to record solicited AE daily for the 1 week following each dose.  
 
 
 
   
 
   
 
 
VAXART  Protocol  Number:  VXA -NVV -[ADDRESS_138032]  2021  Page 42 of 62  Table 8  Events M eeting Definition  of AE 
 
Events Meeting  the AE  Definition 
• Any abnormal  laboratory test  results (hematology,  clinical  chemistry,  or urinalysis)  or other  safety  
assessments (e.g., vital signs measurements) that worsen from baseline and are considered  
clinically significant in  the medical and  scientific judgment of  the investigator.  
• Exacerbation of a chronic or intermittent pre -existing condition including either an increase in 
frequency and/or intensity  of the condition.  
• New conditions detected or diag nosed after study drug administration even though it may have  
been  present before the start of the study.  
• Signs, symptoms,  or the clinical sequelae of  a suspected  intervention - intervention  interaction.  
• Signs, symptoms,  or the clinical sequelae of  a suspected  overdose  of either  study intervention or a 
concomitant medication. Overdose per se will not be reported as an AE/SAE unless it is an  
intentional overdose taken with possible suicidal/self- harming intent. Such overdoses should be 
reported  regardless of sequelae.  
Events NOT  Meeting the  AE Definition 
• Events  that occurred from consent to  pretreatment  
• Medical or surgical procedure (e.g., endoscopy, appendectomy): the condition that leads to the  
procedure  is the AE.  
• Situations in which an untoward medical occurrence did not occur (social and/or convenience  
admission  to a hospi[INVESTIGATOR_307]). 
• Anticipated day -to-day fluctuations of pre -existing disease(s) or condition(s) present or detected at 
the start of the study  that do not w orsen.  
 
VAXART  Protocol  Number:  VXA -NVV -[ADDRESS_138033]  2021   Page 43 of 62  Table 9  Definition  of SAE  
 
An SAE  is defined  as any serious adverse event  that,  at any  dose:  
1. Results in death 
2. Is life-threatening  
The term 'life -threatening' in the definition of 'serious' refers to an event in which the participant was at  
risk of death at the time of the event. It does not refer to an event, which hypothetically might have  
caused  death, if it were  more severe.  
3. Requires inpatient  hospi[INVESTIGATOR_69485] 
• In general, hospi[INVESTIGATOR_12994] (usually involving at  
least an overnight stay) at the hospi[INVESTIGATOR_22771]/or treatment that  
would not have been appropriate in the physician’s office or  outpatient setting. Complications  
that occur d uring hospi[INVESTIGATOR_1084]. If a complication prolongs hospi[INVESTIGATOR_122668], the event is serious. When in doubt as to whether “hospi[INVESTIGATOR_059]” 
occurred  or was necessary, the AE should be considered serious.  
• Hospi[INVESTIGATOR_122669] a pre-existing condition that did not worsen from  
baseline is not considered an AE.  
4. Results in persistent  or significant  disability/incapacity  
An SAE  is defined  as any serious adverse event  that,  at any dose:  
• The term disability means  a substantial  disruption  of a person’s  ability to  conduct  normal  life 
functions.  
• This definition is not intended to include experiences of relatively minor medical significance  
such as uncomplicated headache, nausea, vomiting, diarrhea, influenza, and accidental trauma  
(e.g., sprained ankle) which may interfere with or prevent everyday life functions but do not  
constitute  a substantial disruption.  
5. Is a congenital anomaly/birt h defect  
6. Other  situations:  
• Medical or scientific judgment should be exercised by [CONTACT_122715].  These events should usually be considered  serious.  
o Examples of such events include  invasive  or malignant  cancers,  intensive  treatment  for allergic  
bronchospasm, blood dyscrasias, convulsions or development of intervention dependency or  
intervention  abuse.  
 
 
  
 
  
 
 
VAXART  Protocol  Number:  VXA -NVV -[ADDRESS_138034]  2021   Page 44 of 62  Table 10   Definition of AESI and NOCI  
 
 
 
Table 1 1 Recording  of AE and/or  SAE  
 
AE and SAE Recording  
• When a n AE/SAE occurs, it is the responsibility of the investigator to review all documentation 
(e.g., hospi[INVESTIGATOR_1088], laboratory reports, and diagnostics reports) related to the event.  
• The investigator  will then record  all relevant  AE/SAE/ information.  
• It is not acceptable for the investigator to send photocopi[INVESTIGATOR_10914]’s medical records to  
the Sponsor in lieu of  completion of  the Sponsor  required form.  
• There may be instances when copi[INVESTIGATOR_122670]. In this case, all participant identifiers, with the exception of the participant number, will 
be redacted  on the  copi[INVESTIGATOR_122671].  
• The investigator will attempt to establish a diagnosis of the event based on signs, symptoms, and/or  
other clinical information. Whenever possible, the diagnosis (not the individual signs/symptoms)  
will be documented as the AE/SAE.  
 
   
 
  
 
 
 
 
   
 
 
 
 
   New Onset of Chronic Illness (NOCI)  
• A New Onset of Chronic Illness (NOCI) is defined as diagnosis post -enrollment and vaccination 
of a new medical condition which is chronic in nature, including those potentially controllable by 
[CONTACT_12617] (e.g. diabetes, asthma).  
Adverse Events of Special Interest (AESI)  
• A Significant Event of Special Interest (AESI) is not necessarily ordinarily considered to be a 
SAE, even though the event may be of clinical significance. They are events where Vaxart wishes 
to be promptly informed and to collect information relevant to the event. The same proc ess used 
for reporting SAEs (see Section  8.4.4.  Regulatory Reporting  Requirements  for SAEs ) 
should be followed. Adverse Events of Special Interest are listed within Appendix 5, Section 10.5.  
VAXART  Protocol  Number:  VXA -NVV -[ADDRESS_138035]  2021  Page 45 of 62  Table  12 Grading  the Severity  of AEs  
 
Assessment  of Severity  
All AEs will be assessed by [CONTACT_55296] a protocol -defined grading system. For events not  
included in the protocol -defined grading system, the following guidelines will be used to quantify 
severity:  
Mild : events require minimal or no treatment and do not interfere with the participant’s daily 
activities.  
Moderate: ev ents result in a low level of inconvenience or concern with the therapeutic measures.  
Moderate events may  cause some interference with functioning.  
Severe: e vents interrupt a participant’s usual daily activity and may require systemic drug therapy or  
other  treatment. Severe events are usually incapacitating.  
Life threatening : a ny adverse drug experience that places the participant, in the view of the 
investigator, at immediate risk of death from the reaction as it occurred, i.e., it does not include a  
reaction  that had it occur red in  a more severe form, might have  caused death. 
Changes in the severity of an AE should be documented to allow an assessment of the duration of the  
event at each level of intensity to be performed. Adverse events characterized as intermittent require 
documentation of onset and  duration of each epi[INVESTIGATOR_1865].  
 
Grading  of Solicited  Adverse Events  
Participants should be instructed to rate solicited symptoms of reactogenicity that are collected  
within  their Solicited  Symptom Diary  based  on the  severity  scale presented  in Table  12. 
 
Table 1 3 Grading  of Solicited  Symptoms  of Reactogenicity  
 
 
 
Symptom  Grading  
Normal 
0 Mild  
Grade  1 Moderate  
Grade  2 Severe 
Grade  3 Life Threatening  
Grade  4 
Fever  
(oral  temp)  < 100.4°F  
(< 38.0°C)  100.4 – 101.1°F  
(38.0  – 38.4°C)  101.2 – 102.0°F  
(38.5  – 38.9°C)  102.1 – 104°F  
(39.0  – 40°C)  > 104.0°F 
(>40°C)  
 
 
Headache   
 
None   
No interference with  
activity  Repeated use of  
nonnarcotic pain 
reliever  > 24 hours  or 
some interference 
with activity  Significant; any use of  
narcotic pain reliever  
or prevents daily 
activity   
ER visit or  
hospi[INVESTIGATOR_122672],  
causing minimal 
discomfort and does  
not interfere  with 
everyday  activitiesa Sufficiently  
discomforting to  
interfere  with 
everyday  activities  Prevents  normal 
everyday  activities or 
requires  medical  
advice   
ER visit or  
hospi[INVESTIGATOR_122673]:  VXA -NVV -[ADDRESS_138036]  2021   Page 46 of 62  Nausea/  
Vomiting   
None  No interference with  
activity or 1 to 2  
epi[INVESTIGATOR_1841]/24  hours  Some interference  
with activity or >2  
epi[INVESTIGATOR_1841]/24  hours  Prevents daily activity,  
requires outpatient IV  
hydration ER visit or  
hospi[INVESTIGATOR_122674]   
2 to 3 loose stools  or 
< 400 gms/24  hours   
4–5 stools or 400 
to 800 gms/24  hours  6 or more watery stools  
or > 800gms/24  hours  
or requires outpatient  
IV hydration   
ER visit or  
hospi[INVESTIGATOR_122675]/  
Fatigue  None  No interference  with 
activity  Some  interference  
with activity  Significant;  prevents  
daily  activity  ER visit or 
hospi[INVESTIGATOR_059]  
a Everyday activities  include  attendance  at work,  school  and usual  habits  of the participants.  
 
VAXART  Protocol  Number:  VXA -NVV -[ADDRESS_138037]  2021  Page 47 of 62  N 10.3.1.  Grading  of Laboratory Abnormalities  
In accordance with  the FDA’s  Guidance on the toxicity  grading scale for vaccine studies,  new or 
worsening abnormalities in laboratory values for tests performed and listed in the guidance 
should be graded based on the severity scale presented in  Table 13 (serum chemistry), Table 14 
(hematology) and Table  15 (urinalysis).  
 
Table  14 Grading  of Laboratory Abnormalities  (Serum  Chemistry)  
 
 
Seruma  
Mild  
(Grade  1)  
Moderate  Severe 
(Grade  2) (Grade  3) Potentially Life  
Threatening  
(Grade  4) 
Sodium  – Hyponatremia  mEq/L  132 to  134 130 to  131 125 to 129 < 125 
Sodium  – Hypernatremia  mEq/L  144 to  145 146 to  147 148 to 150 > 150 
Potassium  – Hyperkalemia  mEq/L  5.1 to 5.2 5.3 to 5.4 5.5 to 5.6 > 5.6 
Potassium  – Hypokalemia  mEq/L  3.5 to 3.6 3.3 to 3.4 3.1 to 3.2 < 3.1 
Glucose  – Hypoglycemia  mg/dL  65 to 69 55 to 64 45 to 54 < 45 
Glucose  – Hyperglycemia   Insulin  
Fasting  – mg/dL  100 to 110 111 to 125 >125 requirements  or 
Random  – mg/dL  110 to  125 126 to  200 >200  hyperosmolar  coma  
BUN  mg/dL  23 to 26 27 to 31 > 31 Requires  dialysis  
Creatinine  – mg/dL  1.5 to 1.7 1.8 to 2.0 2.1 to 2.5 > 2.5 or requires  
  dialysis  
Calcium  – hypocalcemia  mg/dL  8.0 to 8.4 7.5 to 7.9 7.0 to 7.4 < 7.0 
Calcium  – hypercalcemia  mg/dL  10.5 to  11.0 11.1 to  11.5 11.6 to  12.0 > 12.0 
Magnesium  – hypomagnesemia  1.3 to 1.5 1.1 to 1.2 0.9 to 1.0 < 0.9 
mg/dL    
Phosphorous  – hypophosphatemia  2.3 to 2.5 2.0 to 2.2 1.6 to 1.9 < 1.6 
mg/dL    
CPK  – mg/dL  1.[ADDRESS_138038]  > [ADDRESS_138039]  
Albumin  – Hypoalbuminemia  g/dL  2.8 to 3.1 2.5 to 2.7 < 2.5 -- 
Total  Protein  – Hypoproteinemia  5.5 to 6.0 5.0 to 5.4 < 5.0 -- 
g/dL    
Alkaline  phosphate  – increase  by 1.[ADDRESS_138040]  > [ADDRESS_138041]  
factor    
Liver  Function  Tests  – ALT,  AST  1.[ADDRESS_138042]  > [ADDRESS_138043]  
increase  by [CONTACT_122716]  – when  accompanied  by 1.[ADDRESS_138044]  1.51 to  1.75 x UL > 1.[ADDRESS_138045]   
increase  by [CONTACT_122716]  – when  Liver  Function  1.[ADDRESS_138046]  1.6 to 2.0 x  2.0 to 3.0 x  > 3.[ADDRESS_138047] is normal;  increase  by [CONTACT_122717]  201 – 210 211 – 225 > 226 --- 
Pancreatic  enzymes  – amylase,  1.[ADDRESS_138048]  1.6 to 2.0 x  2.1 to 5.0 x  > 5.[ADDRESS_138049] = upper limit  of normal 
a The laboratory values provided in the tables serve as guidelines and are dependent upon institutional normal parameters.  
Institutional  normal reference  ranges should be  provided to demonstrate  that they  are appropriate . 
 
VAXART  Protocol  Number:  VXA -NVV -[ADDRESS_138050]  2021   Page 48 of 62  Table 1 5 Grading  of Laboratory Abnorma lities  (Hematology)  
 
 
Hematologya Mild  
(Grade  1) Moderate  
(Grade  2) Severe  
(Grade  3) Potentially Life  
Threatening  
(Grade  4) 
Hemoglobin  (Female),  gm/dL  11.0 to 12.0 9.5 to 10.9 8.0 to 9.4 < 8.0 
Hemoglobin  (Female)  change  Any decrease  to 1.6 to  2.0 2.1 to 5.0 > 5.0 
from  baseline value, gm/dL  1.5    
Hemoglobin  (Male),  gm/dL  12.5 to 13.5 10.5 to 12.4 8.5 to  10.4 < 8.5 
Hemoglobin  (Male)  change  from  Any decrease to  1.6 to  2.0 2.1 to 5.0 > 5.0 
baseline  value,  gm/dL  
3 
WBC increase,  cell/mm  
3 
WBC decrease,  cell/mm  
3 
Lymphocytes  decrease,  cell/mm  
3 
Neutrophils  decrease,  cell/mm  
3 
Eosinophils,  cell/mm  
3 
Platelets  Decreased,  cell/mm  
PT, increase by [CONTACT_122718],  increase  by [CONTACT_122719],  mg/dL  
 
Fibrinogen decrease,  mg/dL  1.5    
10,800  to 15,000 15,001  to 20,000 20,001  to 
25,000  > 25,000 
2,500 to  3,500  1,500 to  2,499  1,000 to  1,499  < 1,000  
750 to 1,000  500 to 749 250 to 499 < 250 
1,500 to 2,000  1,000 to 1,499  500 to 999 < 500 
650 to 1500 1501  to 5000 > 5000 Hypereosinophilic  
125,000  to 140,000 100,000  to 
124,000  25,000  to 
99,000  < 25,[ADDRESS_138051]  > 1.[ADDRESS_138052]  > 1.[ADDRESS_138053]  
400 to  500 501 to 600 > 600 -- 
   < 100 or 
150 to 200 125 to 149 100 to 124 associated  with 
gross  bleeding  
   or DIC 
DIC =  disseminated intravascular coagulation; PT = prothrombin time; PTT = partial thromboplastin time; ULN = upper limit  
of normal; WBC = white  blood  cell 
a The laboratory values provided in the tables serve as guidelines and are dependent upon institutional normal parameters. 
Institutional  normal reference ranges  should be provided to demonstrate that they are appropriate.  
 
Table 1 6 Grading  of Laboratory Abnorma lities  (Urinalysis)  
 
 
Urine*  Mild  
(Grade  1) Moderate  
(Grade  2) Severe  
(Grade  3) Potentially Life Threatening  
(Grade  4) 
Protein  Trace  1+ 2+ Hospi[INVESTIGATOR_122676]  1+ 2+ Hospi[INVESTIGATOR_122677] (microscopic),  
red blood cells  per 
high power  field  
1 to 10  
11 to 50 > 50 and/or  
gross  blood Hospi[INVESTIGATOR_122678]  
a The laboratory values provided in the tables serve as guidelines and are dependent upon institutional normal parameters.  
Institutional  normal reference ranges  should be provided to demonstrate that they are appropriate.  
 
VAXART  Protocol  Number:  VXA -NVV -[ADDRESS_138054]  2021   Page 49 of 62  Table 1 7 Assessment  of Causality 
Assessment of Causality  
• For all solicited symptoms and unsolicited AEs  and SAEs , the Investigator  will make a judgment 
regarding the relationship of the AE to the study vaccine. All AEs must  be recorded in the source 
documents  as well as eCRF.  
• A “reasonable possibility” of a relationship conveys that there are facts, evidence, and/or 
arguments  to suggest  a causal  relationship, rather  than a relationship  cannot  be ruled  out. 
• The investigator  will use clinical  judgment  to determine the relationship.  
• Alternative causes, such as underlying disease(s), concomitant therapy, and other risk factors, as 
well as the temporal relationship of the event to study intervention administration will be  
considered  and investigated.  
• The investigator will also consult the Investigator’s Brochure (IB) and/or Product Information, for  
marketed  products, in his/her assessment.  
• For each AE/SAE, the investigator  must  document  in the medical  notes that he/she has 
reviewed  the AE/SAE and  has provi ded an  assessment of causality.  
• There may be situations in which an SAE has occurred,  and the investigator has minimal  
information to include in the initial report to the Sponsor. However, it is very important that the  
investigator always make an assessmen t of causality for every event before the initial transmission  
of the SAE data to the Sponsor. 
• The investigator may change his/her opi[INVESTIGATOR_9242] -up information and 
send an SAE follow -up report with  the updated causality assessment.  
• The causality assessment is one of the criteria used when determining regulatory reporting  
requirements.  
The relationship  of the AE to study  vaccine administration  will be specified  as follows:  
Not related : In the Investigator’s opi[INVESTIGATOR_1649], there is no causal relationship between study 
vaccine administration and the AE;  
Possibly  Related : The AE follows a reasonable temporal sequence from the time of study  
vaccine administration but there may be another equally likely e xplanation for  
the event (e.g.,  the participant’s  clinical state  or other  medications);  
Probably  Related : The AE follows a reasonable temporal sequence from the time of study  
vaccine administration and cannot be reasonably explained by [CONTACT_122720]’s clinical state;  
Definitely  Related : The AE follows a known temporal sequence from the time of study vaccine administration, cannot be explained by [CONTACT_122721] a recognized  
pharmacological  phenomenon.  
 
 
 
 
  
 
VAXART  Protocol  Number:  VXA -NVV -[ADDRESS_138055]  2021   Page 50 of 62   
 
Table 1 8 Reporting  of SAEs  
SAE  Reporting  to Sponsor  (or designee)  via an Electronic  Data  Collection  Tool 
• The primary mechanism for reporting an SAE to the Sponsor (or designee) will be the electronic 
data collection tool.  
• If the electronic system is unavailable, then the site will use the paper SAE data collection tool  
(see next section) to report the event within 24 hours.  
• The site will enter  the SAE  data into the  electronic system  as soon as it becomes available.  
• After the study is completed at a given site, the electronic data collection tool will be taken off - 
line to prevent the entry of  new data or  changes to existing data.  
• If a site receives a report of a new SAE from a study participant or receives updated data on a  
previously reported SAE after the electronic data collection tool has been taken off -line, then the  
site can report  this information  on a paper SAE  form  (see next section)  or to the  Medical  Monitor  
by [CONTACT_756].  
• Contacts for SAE  reporting  can be found in the Study  Reference Manual  (or equivalent).  
VAXART  Protocol  Number:  VXA -NVV -[ADDRESS_138056]  2021   Page 51 of 62   
10.4. Appendix 4: Contraceptive Guidance and Collection of Pregnancy 
Information  
10.4.1. Definitions  
Woman of Childbearing Potential (WOCBP)  
A woman is considered fert ile following menarche and until becoming post -menopausal unless 
permanently sterilized (see below).  
If fertility is unclear (e.g., amenorrhea in adolescents or athletes) and a menstrual cycle cannot be 
confirmed before first dose of study drug, additional  evaluation should be considered.  
Women in the following categories are not considered WOCBP  
1. Premenarchal  
2. Premenopausal female with 1 of the following:  
• Documented hysterectomy  
• Documented bilateral salpi[INVESTIGATOR_1656]  
• Documented bilateral oophorectomy  
For individuals with permanent infertility due to an alternate medical cause other than the above, (e.g., 
Mullerian agenesis, androgen insensitivity), investigator discretion should be applied to determining 
study entry eligibility.  
Note: Documentation can com e from the site personnel’s review of the participant’s medical records, 
medical examination, or medical history interview. 
 
Postmenopausal  female  
• A postmenopausal state is defined as no menses for [ADDRESS_138057] discontinue HRT to allow confirmation of postmenopausal status 
before study enrollment.  
VAXART  Protocol  Number:  VXA -NVV -[ADDRESS_138058]  2021   Page 52 of 62  10.4.2. Contraception  Guidance  
Female  Subjects  
• A female participant is eligible to participate if she is not pregnant or breastfeeding, and at 
least one of the following conditions applies:  
− Is not a woman of childbear ing potential (WOCBP) 
OR 
− Is a WOCBP and using a contraceptive method that is highly effective (with a failure 
rate of <  1% per year), preferably with low user dependency (see table below), from 
consent through [ADDRESS_138059] dose of study drug, and agrees not to donate eggs 
(ova, oocytes) for the purpose of reproduction during this period. The investigator should evaluate the effectiveness of the contraceptive method in relationship to the 
first dose of study drug.  
− A WOCBP must have negative urine or serum pregnancy test (minimum sensitivity 25 
IU/L or equivalent units of human chorionic gonadotropin [HCG]) at extension 
enrollment visit before first administration of study drug in this study.  
Contraceptive use by [CONTACT_122722]. A reliable form of contraception must 
be approved by [CONTACT_737] (e.g., double barrier method, Depo- Provera, intrauterine device, 
Norpla nt, oral contraceptives, contraceptive patches).  
Male Subjects:  
Male participants are eligible to participate if they agree to the following from informed consent  
through [ADDRESS_138060] dose of study drug:  
• Refrain from donating sperm, except for the purpose of fertility analysis as part of 
this protocol  
PLUS:  
• Be abstinent from heterosexual intercourse as their preferred and usual lifestyle 
(abstinent  on a long term and persistent  basis) and agree to remain  abstinent  
OR 
• Must  agree to  use contracept ion/barrier (a  male condom)  
10.4.3. Collection  of Pregnancy  Information  
Male  participants  with  partners who  become  pregnant:  
• The investigator will attempt to collect pregnancy information on any male 
participant’s  female  partner  who  becomes  pregnant  while  the male  participant is  in 
this study.  
• After obtaining the necessary signed ICF from the pregnant female partner directly, 
the investigator will record pregnancy information on the appropriate form and 
submit it to  the Sponsor within 24 hours of learning of the partner’s pregnancy. The 
Sponsor will  attempt to follow the female partner to determine the outcome of the 
pregnancy. Information on the status of the mother and child will be forwarded to the 
Sponsor. The Sponsor will follow the female partner until bir th or termination of 
VAXART  Protocol  Number:  VXA -NVV -[ADDRESS_138061]  2021   Page 53 of 62  pregnancy when possible. Any termination of the pregnancy will be reported 
regardless of fetal status  (presence or absence of  anomalies)  or indication for  the 
procedure.  
 
Female Subjects who become pregnant  
Any female participant who becomes pregnant while participating in the study will discontinue study 
drug or be withdrawn from the study. Additionally:  
• The investigator will collect pregnancy information, which will be recorded on the 
appropriate form and submitted to  the Sponsor within 24 hours of learning of a participant's 
pregnancy.  
• The participant will be followed to determine the outcome of the pregnancy. The investigator will collect follow -up information on the participant and the neonate,  and the information 
will be forwarded to the Sponsor. The participant will be followed until birth or termination 
of pregnancy. Any termination of pregnancy will be reported, regardless of fetal status (presence or absence of anomalies) or indication for the procedure.  
• While p regnancy itself is not considered to be an AE or SAE, any pregnancy complication or 
elective termination of a pregnancy will be reported as an AE or SAE. A spontaneous abortion is always considered to be an SAE and will be reported as such. Any post -study 
pregnancy related SAE considered reasonably related to the study drug by [CONTACT_122723]. While the investigator is not obligated to actively seek this information in former study participants, he or she may learn of an SAE  through spontaneous 
reporting.  
VAXART  Protocol  Number:  VXA -NVV -[ADDRESS_138062]  2021  Page 54 of 62  10.5. Appendix 5: Adverse  Events  of Special  Interest  (AESIs)  
 
The following adverse events (AEs) for potential immune -mediated medical conditions as well 
as events associated with thrombosis and thrombocytopenia are AEs of special interest (AESIs) 
and include new onset of chronic illness (NOCIs). These events should be monitored for actively throughout the entire study period and reported to the Sponsor in an expedited manner as outlined in Section 10.3. 
 
Gastrointestinal  disorders:  Liver disorders:  
• Celiac  disease • Autoimmune  cholangitis  
• Crohn’s  disease  • Autoimmune  Hepatitis  
• Ulcerative  colitis  • Primary  biliary  cirrhosis  
• Ulcerative  proctitis  • Primary  sclerosing  cholangitis  
Metabolic  diseases:  
• Addison’s  disease • Diabetes mellitus type  1 
• Autoimmune thyroiditis (including  
Hashimoto thyroiditis)  • Grave’s  or Basedow’s  disease  
Coagulopathy:   
• Acquired amegakaryocytic 
thrombocytopenia  • Amegakaryocytic thrombocytopenia  
• Axillary vein thrombosis  • Cavernous sinus thrombosis  
• Cerebral venous thrombosis  • Deep vein thrombosis  
• Disseminated intravascular coagulation  • Embolism venous  
• Hepatic vein thrombosis  • Immune thrombocytopenia  
• Intracranial venous sinus thrombosis  • Mesenteric vein thrombosis  
• Portal vein thrombosis  • Pulmonary embolism  
• Pulmonary thrombosis  • Pulmonary venous thrombosis  
• Severe fever with thrombocytopenia 
syndrome  • Subclavian vein thrombosis  
• Thrombocytopenia  • Thrombocytopenia purpura  
• Thrombotic thrombocytopenia purpura  • Thrombosis  
• Transverse sinus thrombosis  • Vena cava embolism  
• Vena cava thrombosis  • Venous thrombosis  
Musculoskeletal  disorders:  
• Antisynthetase  syndrome  • Polymyalgia  rheumatic  
• Dermatomyosotis  • Polymyositis  
• Juvenile chronic arthritis (including Still’s  
disease)  • Psoriatic  arthropathy 
• Mixed  connective  tissue  disorder  • Relapsing  polychondritis  
• Scleroderma, including diffuse systemic  
form  and CREST  Syndrome  • Rheumatoid  arthritis  
• Systemic  lupus  erythematous  • Systemic  sclerosis  
• Spondyloarthritis,  including  ankylosing  spondylitis,  reactive  arthritis  (Reiter’s  Syndrome)  and 
undifferentiated spondyloarthritis.  
 
VAXART  Protocol  Number:  VXA -NVV -[ADDRESS_138063]  2021  Page 55 of 62   
Neuroinflammatory  disorders:  
• Acute disseminated encephalomyelitis, including site specific variants (e.g., non -infections encephalitis,  
encephalomyelitis, myelitis,  myeloradiculomyelitis)  
• Immune related peripheral neuropathies and plexopathies, including chronic inflammatory demyelinating 
polyneuropathy, multifocal motor neuropathy and polyneuropathies associated with monoclonal  
gammopathy  
• Cranial nerve disorders, including  
paralysis/paresis  (e.g.,  Bell’s  palsy)  • Guillain -Barre syndrome, including Miller 
Fisher  syndrome  and other  variants  
• Multiple  sclerosis  • Narcolepsy  
• Optic  neuritis  • Transverse  Myelitis  
• Myasthenia  gravis,  including  Eaton -Lambert  syndrome  
Skin disorders:  
• Autoimmune  bullous  skin diseases  
(including pemphigus, pemphigoid and 
dermatitis  herpetiformis  • Rosacea  
• Alopecia  aerate  • Cutaneous  lupus  erythematosus  
• Erythema  nodosum  • Psoriasis  
• Morphoea  • Sweet’s  syndrome  
• Lichen  planus  • Vitiligo  
VAXART  Protocol  Number:  VXA -NVV -[ADDRESS_138064]  2021  Page 56 of 62  Vasculitis:  
• Large  vessels  vasculitis  including  giant  cell arteritis  such as Takayasu’s  arteritis  and temporal  arteritis  
• Medium sized/and or small vessels vasculitis including polyarthritis nodosa, Kawasaki’s disease,  
microscopic polyangiitis, Wegener’s granulomatosis, Churg -Strauss syndrome (allergic granulomatous  
angititis),  Buerger’s  disease thromboangitis  obliterans),  nerotizing  vasculitis  and anti-neutrophil  
cytoplasmic antibody (ANCA) positive vasculitis (type unspecified), H enoch -Schonlein purpura, Behcet’s  
syndrome,  leulocytoclassic  vasculitis  
Others:  
• Autoimmune glomerulonephritis (including IgA nephropathy, glomerulonephritis rapi[INVESTIGATOR_10480],  
membranous  glomerulonephritis,  membranaoprolifative  glomerulonephritis,  and mesangioproliferative  
glomerulonephritis)  
• Antiphospholipid  syndrome  • Pernicious  anemia  
• Autoimmune  hemolytic  anemia  • Raynaud’  phenomenon  
• Autoimmune  myocarditis/cardiomyopathy  • Sarcoidosis  
• Autoimmune  thrombocytopenia  • Sjogren’s  syndrome  
• Goodpasture  syndrome  • Stevens -Johnson  Syndrome  
• Idiopathic  pulmonary  fibrosis  • Uveitis  
VAXART  Protocol  Number:  VXA -NVV -[ADDRESS_138065]  2021  Page 57 of 62  10.6. Appendix 6: Abbreviations  
 
Term  Description  
Ad5 Adenovirus  type [ADDRESS_138066]  
ANCA  Anti-neutrophil  cytoplasmic  antibody  
ASC  Antibody  secreting  cells 
BMI  Body mass  index  
CBER  Center  for Biologics  Evaluation and  Research  – FDA  
CIOMS  Council  for International  Organizations  of Medical  Sciences  
DP Drug  product  
eCRF  Electronic  case report form  
ELISA  Enzyme -linked  immunosorbent  assay  
ELISpot  Enzyme -linked  immunospot  
EOS  End of Study  
ET Early Termination  
FDA  Food  and Drug  Administration  
GCP  Good  Clinical  Practice  
GI.[ADDRESS_138067] 
HIV Human  immunodeficiency  virus  
IB Investigator’s  brochure  
ICF Informed  Consent  
ICH International  Council  for Harmonisation  
SMC  Safety  Monitoring  Committee  
IEC Independent  Ethics  Committee  
VAXART  Protocol  Number:  VXA -NVV -[ADDRESS_138068]  squares  
MedDRA  Medical  Dictionary  for Regulatory Activities  
NOCI  New  Onset  of Chronic  Illness  
NoV  Norovirus  
PBMC  Peripheral  blood  mononuclear  cells 
PF4 Antibody 
ELISA  Platelet Factor 4 antibody ELISA  
PT/INR  Prothrombin time and international normalized ratio  
RBD  Receptor  binding  domain  
RCA  Replication -competent  Ad5 
RCC  Radio -Controlled  Capsules  
RNA  Ribonucleic  acid 
RT-PCR  Reverse  transcription  polymerase  chain reaction  
SAE  Serious  adverse  event  
SAP Statistical  analysis plan  
SARS -CoV -[ADDRESS_138069]  technology  
VP1 Vaccine  Protein  1, major  capsid  protein  of norovirus  
WOCBP  Women of childbearing potential  
 
 
 
 
  
 
  
 
 
 
 
 
 
VAXART  Protocol  Number:  VXA -NVV -[ADDRESS_138070]  2021   Page 59 of 62   
 
 
10.6  Appendix 7: Summary of Changes to Protocol  
 
 
PROTOCOL VXA -NVV -105 HISTORY : 
Document   Date   
Protocol A mendment 1; Version 2.[ADDRESS_138071]  2021 
Original Protocol; Version 1.0   31 March  2021 
  
Overall Rationale for the Amendment:  
 
Per a request received from the FDA, Vaxart  has amended this clinical protocol to incorporate 
information on the risk of  Thrombosis with Thrombocytopenia Syndrome (TTS) that has been observed 
with administration of two injected adenovirus -vectored COVID- 19 vaccines being used under EUA. 
Enrollment under this protocol has  completed , however  subjects are currently in safety follow -up. All 
subjects will be reconsented with an updated informed consent form with updated risk information incorporating TTP at their next site visit. This requirement for updatd risk information  has necessitated 
the modifications listed in the table below within protocol amendment 1 ( Ver. 2.0). Additional minor 
changes incorporated into the amendment for added consistency/clarity are also summarized below.  
Section No. & T itle Description of Change   Brief Rationale  
Table 1 .2: Schedule 
of Activities   Table 1 has been updated to include 
allocation of a n aliquot of serum collected at 
baseline to be stored for testing (e.g. PF4 
antibody ELISA) should an AESI related to 
blood clots be reported anytime during the 
study period.   Per the direction of the FDA, a blood 
sample should be collected at baseline 
and stored for analysis should a 
participant experience a clotting adverse event.  
2.3 Benefit/ Risk 
Assessment  The risk section has been updated to include 
language describing the adverse events 
reported with two injected adenovirus -
vectored vaccines ( thromboembolism and/or 
thrombocytopenia) , as well as with general 
information on how to monitor for and report the events should they occur in study 
participants.  Because Vaxart’s VXA -G1.1 -NN 
investigational vaccine utilizes an  
adenovirus vectored design, and per the 
director of the FDA, information on the 
risks of thromboembolism and /or 
thrombocytopenia have been added to 
Section 2.1 of the protocol.  
Appendix 5: 
Adverse Events of Special Interest 
(AESIs)  The List of Adverse Events of Special 
Interest (AESIs) has been updated to include 
events to be monitored under the category of 
Coagulopathy  
 Per the guidance received from  FDA , 
the list of AEs of special interest (AESIs) 
has been updated to require  sites to 
monitor study participants for the 
occurrence of TTS events. 
   
 
  
VAXART  Protocol  Number:  VXA -NVV -[ADDRESS_138072] been incorporated within the current amendment to provide 
increased clarity and consistency:  
 
Section No. & T itle Description of Change   
Inclusion Criteria  #5 and 6.1.  Appendix 
4: Contraceptive Guidance and 
Collection of Pregnancy Information Clarification added to inform  that a pregnancy test should be 
conducted on all female participants and therefore the follicle -
stimulating hormone (FSH) testing will not be required. The 
women of childbearing potential category will no longer be utilized 
as a differential marker for pregnancy testing  
Inclusion Criteria #2  Inclusion criterion #2 which refers to subjects “without significant 
medical” was  revised to be  worded  consistent with  exclusion 
criteri on #1 which states subjects with “significant uncontrolled 
medical” should be excluded  
Section 1.1 Overall Design  There was language present in  error on page 8 of the original 
protocol which states that “absence of acute illness or new medical 
condition as confirmed by [CONTACT_122724] -CoV-2 if 
symptomatic”. SARS-CoV-2 negative testing is not a defining 
criterion for absence of acute illness or new medical condition and 
is not included elsewhere in the protocol. This erroneous language 
has been removed  in the current  amendment.  
Table 1.2: Schedule of Activities  A serum or urine pregnancy test is acceptable prior to both the first 
and second vaccinations.  This has been clarified within the 
amendment.  
Section 8.[ADDRESS_138073] ed as part of the Vital Sign 
procedures  
Table 1.2: Schedule of Activities  For Day 57 vaccination day (Cohort 2) the super script has been 
corrected to  “e” from  “3”, which was in error . 
Table 1.2: Schedule of Activities  Alcohol testing , required to evaluate the associated exclusion 
criteria , was included in the protocol however not listed out as a 
separate assessment within the Schedule of activities . It has been 
added there  for consistency  and added clarity.  
Exclusion Criteria #14  Exclusion criteri on #[ADDRESS_138074] at their Day 1 visit.  
Section 10.1.3 Informed Consent Process  Language  regarding the  use of a second ICF has been deleted as a 
separate consent for future use  is not applicable to this protocol . 
The current ICF form already addresses storage of samples for 
future use . 
 
 
VAXART  Protocol  Number:  VXA -NVV -[ADDRESS_138075]  2021   Page 61 of 62  11. REFERENCES  
Bányai, K., Estes, M. K., Martella, V. and Parashar, U. D. (2018). "Viral gastroenteritis." Lancet  
392([ZIP_CODE]): 175- 186. 
Bresee, J. S., Widdowson, M. A., Monroe, S. S. and Glass, R. I. (2002). "Foodborne viral 
gastroenteritis: challenges and opportunities."  Clin Infect  Dis 35(6):  748-753. 
Callaway . (2020) . “The race for coronavirus vaccines: a graphical guide: Eight ways in 
which scientists hope to provide immunity to SARS -CoV- 2”. Nature 580:  576- 577. 
de Graaf, M., van Beek, J. and Koopmans, M. P. (2016). "Human norovirus transmission and 
evolution in  a changing world."  Nat Rev Microbiol  14(7):  421-433. 
Esposito, S.  and Principi,  N. (2020). "Norovirus  Vaccine:  Priorities  for Future  Research  and 
Development."  Front Immunol 11: 1383. 
Gaythorpe, K. A. M., Trotter, C. L., Lopman, B., Steele, M. and Conlan, A. J. K. (2018). 
"Norovirus  transmission  dynamics:  a modelling review."  Epi[INVESTIGATOR_19277]  146(2):  147-158. 
Glass, R. I., Parashar, U. D. and Estes, M. K. (2009). "Norovirus gastroenteritis." N Engl J Med 
361(18): 1776- 1785. 
Hoa Tran, T. N., Trainor, E., Nakagomi, T., Cunliffe, N. A. and Nakagomi, O. (2013). "Molecular epi[INVESTIGATOR_122679] c gastroenteritis in  
children: global distribution of genogroups, genotypes and GII.4 variants." J Clin Virol 56(3):  
185-193. 
Hung and Poland. ( 2021 ). “Single -dose Oxford– [COMPANY_008] COVID- 19 vaccine followed 
by a 12- week booster .” The Lancet 397([ZIP_CODE]) : 854- 855. 
Kim,  L., Liebowitz,  D., Lin,  K., Kasparek,  K., Pasetti,  M. F., Garg,  S. J., et  al. (2018).  "Safety  
and immunogenicity of an oral tablet norovirus vaccine, a phase I randomized, placebo - 
controlled  trial." JCI Insight  3(13):  e121077. 
Kim, L., Martinez, C. J., Hodgson, K. A., Trager, G. R., Brandl, J. R., Sandefer, E. P., et al. (2016). "Systemic and mucosal immune responses following oral adenoviral delivery of  
influenza vaccine to the human intestine by [CONTACT_122725] d capsule." Scientific Re ports 6(1): 
[ZIP_CODE]. 
Liebowitz,  D., Gottlieb,  K., Kolhatkar, N.  S., Garg,  S. J., Asher,  J. M., Nazareno,  J., et al. (2020).  
"Efficacy and immune correlates of protection induced by [CONTACT_122726]  
a phase 2, pl acebo -controlled human experimental infection study." Lancet Infect Dis 20: 435-  
444. 
Lopman, B.  A., Steele,  D., Kirkwood, C.  D. and Parashar,  U. D. (2016). "The  Vast  and Varied  
Global Burden of Norovirus: Prospects for Prevention and Control." PLoS Med 13(4):  
e1001999. 
Miettinen, O. and Nurminen, M. (1985). "Comparative analysis of two rates." Stat Med 4(2):  
213-226. 
Teunis, P. F., Moe, C. L., Liu, P., Miller, S. E., Lindesmith, L., Baric, R. S., et al. (2008). 
"Norwalk  virus: how  infectious is  it?" J  Med  Virol  80(8):  1468-1476. 
Vega, E., Barclay, L., Gregoricus, N., Shirley, S. H., Lee, D. and Vinje, J. (2014). "Genotypic  
VAXART  Protocol  Number:  VXA -NVV -[ADDRESS_138076]  2021   Page 62 of 62  and epi[INVESTIGATOR_122680], 2009 to 2013." J Clin 
Microbiol 52(1): 147 -155. 
Voysey, et al., ( 2021). “Single -dose administration and the influence of the timing of the 
booster dose on immunogenicity and efficacy of ChAdOx1 nCoV -19 (AZD1222) vaccine: a 
pooled analysis of four randomised trials.” The Lancet 397([ZIP_CODE]): 881 -891. 